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GATA transcription factors are evolutionary highly conserved zinc-finger proteins. 
They are essential for the normal differentiation of various tissues, and their aberrant 
expression has been connected to several diseases including malignancies. GATA4 
and GATA6 are indispensable for early development of the mammalian liver, but their 
expression is low in normal postnatal hepatocytes.  
 
Hepatoblastoma (HB) is a rare liver malignancy of small children, with a largely 
unknown etiology and molecular pathology. Histologically HBs resemble fetal or 
embryonal liver tissue synthesizing alphafetoprotein, used as a diagnostic marker. 
Biliary atresia (BA) is a neonatal cholestatic condition caused by fibroinflammatory 
obstruction of the extrahepatic bile ducts, with subsequent histological changes in 
liver, including fibrosis and expansion of the intrahepatic bile ductules.   
 
In this thesis work, we demonstrate that GATA4 is frequently overexpressed in 
childhood HB unlike in normal liver hepatocytes or adulthood liver tumors. The 
effects of GATA4 in HB cell malignancy were studied in vitro utilizing an established 
human HB cell line HUH6. GATA4 expression was modified in these cells by siRNA, 
adenoviral vectors, or plasmid constructs. The changes in cell function and gene 
expression were subsequently analyzed. We found that GATA4 1) protects HB cells 
from the commonly used cytostatic drug doxorubicin by regulating the BCL2 protein 
family balance in the intrinsic apoptotic pathway, and 2) shifts the transcriptomic 
profile of HB cells to more mesenchymal-type and enhances their migration, thus 
promoting cancer cell survival and metastasis.  
 
A second focus of this thesis is the role of GATA6 transcription factor in BA 
pathogenesis. We found that GATA6, normally restricted to biliary epithelium in 
postnatal liver, is highly expressed in the hepatocytes of BA patients, i.e. in regions of 
ductal metaplasia known to lead to pathological changes in BA livers. GATA6 
expression levels correlate to known prognostic markers, including bile ductule 
expansion and age at portoenterostomy. The expression of GATA6 decreases 
significantly after successful portoenterostomy and resolution of cholestasis. 
Analogously to its increased expression in BA, GATA6 is also upregulated in the 
hepatocytes of two mouse models with biliary obstruction. Furthermore, forced 
expression of GATA6 in human primary hepatocytes and human hepatoma cell line 
HepG2 drives their gene expression towards cholangiocyte lineage.  
 
Taken together, transcription factors GATA4 and GATA6 are essential for the initial 
differentiation of hepatoblasts and for liver organogenesis. Expression of GATA4 and 
GATA6 is low in normal postnatal hepatocytes, but in these two pediatric diseases of 
the liver, HB and BA, their expression is upregulated respectively. Overexpression of 
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these GATA factors affects the gene expression of hepatocytes, and thus are putative 
drivers of hepatocyte metaplasia and neoplasia. This thesis work clarifies the 
mechanisms by which GATA4 promotes the malignant phenotype of HB cells and 
demonstrates GATA6 as a marker and driver of hepatocyte ductal metaplasia in biliary 
atresia.
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ADD3 = adducin 3 
AFP = alpha-fetoprotein 
ALB = albumin 
ALT = alanine amino transferase 
BA = biliary atresia 
BCL2 = B-cell lymphoma 2 
BDE = bile ductule expansion 
BDL = bile duct ligation 
BMP = bone morphogenic protein 
CFC1= cryptic family 1 
COL4α1 = collagen 4 alpha 1 
CK = cytokeratin 
DKK1 = dickkopf-related protein 1  
DLK1 = delta-like non-canonical Notch ligand 1 
DOCK8 = dedicator of cytokinesis 8 
Dox = doxorubicin 
DR = ductular reaction 
E = embryonal day 
E-cad = epithelial cadherin = CDH1 
ECM = extra-cellular matrix 
EMT = epitehlial-mesenchymal transition 
EpCAM = epithelial adhesion molecule 
EPO = erythropoietin 
FABPL = fatty acid-binding protein, liver type  
FAP = familial adenomatous polyposis coli 
FGF = fibroblast growth factor 
FFPE = formalin-fixed paraffin embedded 
FN1 = fibronectin 1 
FOG = friend of GATA 
GPC1 = glypican 1 
GW = gestational week 
HB = hepatoblastoma 
HCC = hepatocellular carcinoma 
HGF = hepatocyte growth factor 
HNF = hepatocyte nuclear factor 
HSC = hepatic stellate cell 
HTT-I = hereditary tyrosinemia type 1 
IGFBP1 = insulin-like growth factor binding protein 1 
INVS = inversin 
LSEC = liver sinusoidal endothelial cell 
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MMP1 = matrix metalloproteinase 1 
N-cad = neural cadherin = CDH2 
NFE2L2 = Nuclear factor (erythroid-derived 2)-like 2 
P = postnatal day 
PE = portoenterostomy 
PFIC = progressive familial intrahepatic cholestasis 
PROM1 = prominin 1 
RHO = Ras homolog family member 
siRNA = small interfering RNA 
SOX9 = SRY-box 9 
SYTL2 = synaptotagmin-like 2 
TGF = transforming growth factor 
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The liver organogenesis consists of seven stepwise phases. They include a priming 
phase, a phase of increasing specification, expansion of the liver bud, migration of 
hepatoblasts into the transverse septum mesenchyme, a phase of liver vascularisation, 
an organ growth phase, and the terminal differentiation of the hepatocyte and 
cholangiocyte lineages [reviewed in (1)].  
 
Three germ layers are formed during gastrulation: ectoderm, mesoderm, and 
endoderm. Liver is derived from the ventral foregut formed from the definitive 
endoderm. To start the programming towards hepatoblasts, the cells of the foregut 
endoderm require inductive signals, including fibroblast growth factors (FGF) and 
bone morphogenic proteins (BMP), from the adjacent cardiogenic mesoderm (2) and 
septum transversum mesenchyme (3), respectively. In response to these signals, a 
primary liver bud is formed from the progenitor cells in the ventral wall of the foregut. 
In a mouse embryo, this formation of the liver bud occurs by embryonic day (E) 8.5-
9.0 (4). Among several other transcription factors, GATA4 and GATA6 are crucial 
for the expansion of the liver bud and the early hepatic development (5). After the 
invasion of the hepatoblasts of the liver bud to septum transversum, they start to 
organize to form the specific architecture of the mature liver. This requires the 
differentiation of the various liver cell types. Simultaneously, the liver volume grows 
rapidly, requiring extensive proliferation of the hepatocyte cell population [reviewed 
in (4)]. 
 
Hepatoblasts are the bipotential precursors of both epithelial cell types of the liver, 
hepatocytes and cholangiocytes. The process of cell fate determination of fetal 
hepatoblasts is not completely clear, but several signaling pathways and transcription 
factors are implicated as inductors of both cell lineages.  The biliary differentiation is 
dependent on Notch and Wnt/β-catenin signaling pathway components, and 
hepatocyte nuclear factors (HNF) 1β and HNF6 [reviewed in (6)], whereas hepatocyte 
differentiation is driven by hepatocyte growth factor (HGF), HNF3, HNF4α, and 
HNF1α [reviewed in (7)] (Figure 1).  
 




Figure 1. Differentiation of hepatocytes and cholangiocytes from common progenitor cells. 
Expression of distinct cellular markers and inducing factors/pathways at different stages of liver 
development. ENDM=endoderm-specific surface marker, E-cad=E-cadherin, PROM1=prominin 1, 
HEX= Hematopoietically Expressed Homeobox, HNF=hepatic nuclear factor, AFP=alfafetoprotein, 
ALB=albumin, DLK1=Delta Like Non-Canonical Notch Ligand 1, EpCAM=epithelial cell adhesion 
molecule, FGF=fibroblast growth factor, BMP=bone morphogenic protein, HGF=hepatocyte growth 
factor, C/EBPα=CCAAT/enhancer binding protein α, CK=cytokeratin, SOX9=SRY-box 9, 
TGFβ=transforming growth factor β. Modified from (8). Created using image vectors from Servier 
Medical Art (http://smart.servier.com/), licensed under the Creative Commons Attribution 3.0 
Unported License. 
1.2   Gross anatomy 
 
Liver is the largest intestinal organ of the body, accounting approximately 2-3% of 
body weight in adults, and up to 5-6% in children. The liver is enclosed in the capsule 
of Glisson and located in the upper right quadrant of the abdominal cavity. It consists 
of left and right lobes, separated by the falciform ligament, attaching the liver to 
anterior abdominal wall (Figure 2). The liver is further divided into eight segments 
based on its blood supply, and each segment is supplied by a portal triad (portal vein, 
bile duct, and hepatic artery) (9). The liver has a dual blood supply, from common 
hepatic artery (30%) originating from the caeliac trunk, and from the portal vein 
(70%), bringing blood from the other intestinal organs. Three major hepatic veins 
drain the blood from the liver to the inferior vena cava (Figure 2) (9). 
 
Bile flow starts from the intrahepatic bile canaliculi and moves on to larger 
interlobular ducts. These ducts combine to form left and right hepatic duct and further 
REVIEW OF THE LITERATURE 
 14 
a common hepatic duct outside the liver. The gallbladder is connected to this duct to 
form a common bile duct carrying bile to the small intestine (Figure 2) (10). 
 
 
Figure 2. Anatomy of the liver and extrahepatic bile ducts. 
Created using image vectors from Servier Medical Art (http://smart.servier.com/), licensed under the 
Creative Commons Attribution 3.0 Unported License. 
1.3   Physiology and function  
Liver has several vital functions [reviewed in (11)]. In the fetal period, erythropoiesis 
takes place in the liver (12). Postnatally, liver controls the metabolism of 
carbohydrates, proteins, and lipids. Cholesterol and other lipids, as well as several 
important serum proteins, like coagulation factors and albumin are produced by the 
liver. Furthermore, liver serves as a storage of many essential vitamins and minerals, 
glycogen and fatty acids, and it maintains the blood homeostasis of glucose. Bile, 
consisting of water, bile salts, cholesterol, and bilirubin, is necessary for lipid digestion 
and secreted from the liver to small intestine. Several hormones are produced in the 
liver. Liver has an important detoxification function; it metabolizes drugs, alcohol, 
and other toxic agents. All extrinsic molecules absorbed in the intestine are passed 
through portal vein to liver before entering the systemic circulation. Liver 
macrophages, Kupffer cells, are an important part of the immune system, and they 
digest microbes from the blood flowing through the liver.  
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1.4  Histology and cell types 
1.4.1 Cellular anatomy 
 
The liver consists of three functional systems: 1) hepatocyte system, 2) biliary system, 
and 3) blood circulatory system [reviewed in (13)]. Hepatocytes are arranged in hexa- 
or pentagonal structural units, called hepatic lobules. Central vein is in the middle of 
each lobule, surrounded by radiating colums of hepatocytes, and 4-6 portal triads 
(consisting of a branch of portal vein, hepatic artery, and bile ductule). Hepatocytes of 
the lobule are divided into three zones based on their location, and thereafter their 
nutrient and oxygen saturation, metabolic and regeneration activity, and pronity to 
toxins. This functional unit is called a hepatic acinus (Figure 3). 
 
  
Figure 3. Structural and functional architecture of the liver: lobule and acinus. 
Lobules are hexagonal structural units of the liver, consisting of hepatocyte columns with a central vein 
in the middle, and surrounded by portal triads. Acini are the functional units of the liver, consisting of 
three zones of hepatocytes according to their location to portal vein and central vein. Created using 
image vectors from Servier Medical Art (http://smart.servier.com/), licensed under the Creative 
Commons Attribution 3.0 Unported License. 
 
 
The blood entering the lobule from portal vein, flows through spaces between the 
hepatocytes called sinusoids, and drains to the central vein. The area between the 
sinusoidal endothelial cells and the hepatocyte columns is called the space of Disse. 
Between adjacent hepatocyte columns is a tubular bile canaliculi structure, where the 
bile flows to opposite direction with blood, ending up in bile ducts on the periphery of 
the lobule (Figure 4). 
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Figure 4. Structure and cell types of the liver lobule. 
Bile flows in bile ductules (arrow with dashed line) to opposite direction with blood in sinusoids (arrow 
with solid line). Created using image vectors from Servier Medical Art (http://smart.servier.com/), 
licensed under the Creative Commons Attribution 3.0 Unported License. 
1.4.2 Hepatocytes 
Hepatocytes are the parenchymal cells of the liver that comprise almost 80% of the 
liver volume and 60% of the cell population. Hepatocytes are derived from bipotential 
stem cells of the liver, hepatoblasts, by gradually acquiring liver-enriched 
transcription factors. These factors regulate gene expression of the developing 
hepatocytes to gain the several vital functions of mature hepatocyte [reviewed in (7)]. 
Hepatocytes are the functional units of the liver. They are cuboidal, structurally and 
functionally polarized epithelial cells that have endocrine and exocrine properties (4). 
Adjacent hepatocytes are connected with intercellular junctional complexes. 
Hepatocytes have a great regeneration ability after injury. The regenerative 
hepatocytes derive from mitotic activity of mature hepatocytes, cholangiocytes and 
endothelial cells, but when the proliferative capacity of the mature hepatocytes is 
impaired, hepatic progenitor cells i.e. oval cells, can participate to the regenerative 
process by differentiating to hepatocytes (14). 
1.4.3 Cholangiocytes  
 
Cholangiocytes are epithelial cells lining the intrahepatic and extrahepatic bile ducts. 
They are highly polarized and joined together near the apical surface by tight 
junctions. The primary bile secreted by hepatocytes is transported into bile canaliculi, 
where it is alkalinized and fluidized by the cholangiocytes (15). Cholangiocytes are 
functionally and morphologically heterogenous along the biliary tree. The 
cholangiocytes lining small bile ducts have a more reactive phenotype and are able to 
proliferate and re-differentiate in case of hepatic injury or pathological stimuli (16). 
Like hepatocytes, the intrahepatic cholangiocytes are derived from hepatoblasts. In 
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contrast, cholangiocytes lining the extrahepatic bile ducts share a common 
developmental origin with the pancreas and duodenum (17). When a hepatoblast has 
committed to differentiate to cholangiocyte, it starts to express cholangiocyte markers, 
like cytokeratins (CK) 7 and 19.  
1.4.4 Other cell types of the liver 
 
In addition to cholangiocytes; sinusoidal endothelial cells, hepatic stellate cells 
(HSCs), hepatic progenitor cells (HPCs), Kupffer cells, and pit cells (liver-specific 
natural killer cells) represent the majority of non-hepatocyte cell types in the liver. 
Liver sinusoidal endothelial cells (LSEC) are fenestrated, highly specialized 
endothelial cells, located between the hepatocytes and HSCs. They control the tone of 
the hepatic vasculature and keep the portal pressure stable. LSECs also control the 
activation of HSCs, and thus contribute to the onset of liver fibrosis in disease state 
[reviewed in (18)]. 
HSCs, also know as Ito cells, are located in the space of Disse, and in normal quiescent 
state they function as storage of vitamin A. HSCs are activated under liver damage, 
when they differentiate into proliferating portal myofibroblasts, producing ECM 
components, and thus have an important role in development of liver fibrosis. HCSs 
also participate in inflammation and immune regulation of the liver (19).  
HPCs are bipotential cells residing in the canals of Hering in the normal liver, able to 
participate in hepatocyte or cholangiocyte renewal. Their proliferation is evident in 
primary liver cancer and reactive conditions of the liver [reviewed in (20)]. 
Kupffer cells are liver macrophages and a part of the reticuloendothelial system. They 
phagocytose microbes and aged erythrocytes. Kupffer cells are localized inside the 
liver sinusoids, and in a healthy liver they do not response to every immunologic 
stimulus derived from the intestinal blood flow. In chronic inflammatory diseases, 
Kupffer cells are activated and lose the tolerogenic phenotype, thus start sending 
signals through the endothelial cells for the hepatocytes and stellate cells, enhancing 
the pathologic fibrogenesis and liver injury [reviewed in (21)].  
The different cell types of the liver constantly interact with one other; this intercellular 
signaling is essential for normal functions of the liver, but it is also likely to 
significantly contribute to the pathological processes occurring during liver disease 
and injury (22, 23). 
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2 PEDIATRIC LIVER PATHOLOGY 
Liver pathology in children is divided into neonatal conditions and diseases occurring 
in older children. The most frequent causes of liver pathology in these two groups are 
listed in table 1.  
 
Table 1.  Frequent causes of pediatric liver disease according to age. 
Modified from (24). 
 
Neonates and infants Older children and adolescents 
Cholestatic diseases 
• Biliary atresia 
• Paucity of the intrahepatic bile ducts 
• Cholelithiasis 
• Progressive familial intrahepatic 
cholestasis (PFIC) 







Toxins and pharmacologic remedies 
Fatty liver of obesity 
Idiopathic neonatal hepatitis Occlusion of the hepatic veins 
Viral hepatitis and other infectious diseases 
in the neonate 
Wilson disease 
Methabolic disease Hypotension/ischemia/cardiac 
failure 
Toxic or pharmacologic injury Fatty liver of pregnancy 
Tumors 
• Malignant: hepatoblastoma, 
hepatocellular carcinoma, embryonal 
rhabdomyosarcoma 
• Benign: hemangioendothelioma, 
mesenchymal hamartoma 
Malignant tumors 





2.1.1 Incidence and etiology 
 
Hepatoblastoma (HB) is a pediatric liver tumor with an incidence of 1.7 per million 
children per year (25). Although rare, it accounts for nearly 70% of all malignant 
tumors of the liver in children (26). Most HB cases occur before the age of four, the 
median age of diagnosis being 1.5 years (27). They are 1.5-times more common 
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among boys than girls for unknown reason, and in nearly all cases there is no family 
history of HB (25).  
 
The embryonal/fetal histology and the young age of the patients imply that genetic 
and developmental factors play a role in HB pathobiology. There are rare cases of HB 
in school-aged children and adolescents, but they commonly have features of both HB 
and hepatocellular carcinoma (HCC) and are thus called translational liver tumors 
(27). HCC is the most common liver cancer in adulthood, with an etiology based on 
the predisposing hepatic injury or cirrhosis by exposure to viruses or toxic agents (26).  
 
Most HB cases are sporadic, but HB occurrence is also connected to congenital 
syndromes, like Beckwith-Wiedemann and Sotos overgrowth syndromes (28, 29) and 
familial adenomatous polyposis coli (FAP) (30). There are several studies about the 
perinatal risk factors for HB and their results vary, as HB is connected to prematurity 
(25, 31), maternal factors during pregnancy (32), and congenital anomalies (31, 33, 
34) i.a. Only low birth weight has been implicated as a risk factor in several studies 
(25, 32, 33, 35, 36).  
2.1.2 Histological subtypes 
 
HBs are very heterogenous tumors and one tumor can consist of several histologically 
distinct areas. HBs can be divided into two main groups: pure epithelial (56%) or 
mixed epithelial/mesenchymal (44%) tumors (Table 2) (37, 38).  
 
The epithelial component can either resemble different developmental stages of 
embryonal or fetal liver or can be small cell undifferentiated (SCUD) or 
macrotrabecular subtype. Embryonal and fetal subtypes present hepatocyte lineage 
cells with immature, blastic features. Extramedullary hematopoiesis is present in these 
subtypes (38). Pure fetal subtype has the most favorable prognosis (39), and can be 
treated surgically without chemotherapy (40). SCUD cell subtype consists of highly 
proliferative stem cell-like cells with low AFP production, and its presence in tumor 
predicts a poor prognosis (41). Macrotrabecular HB, often presenting HCC or 
translational tumor-like features, is named after the growth pattern of the epithelial 
cells (38).  
 
The mixed epithelial-mesenchymal tumors include neoplastic areas of stromal 
components, mainly immature osteoid, fibroblastoid, or myofibroblastoid loci. Less 
frequently, cartilagous or rhabdomyoplastic tissue may be present (37). 
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Table 2. HB histological classification according to SIOPEL liver tumor group. 
Modified from (38). 
 
HB histological subtypes  
Epithelial HB 
Pure fetal  
Mixed embryonal/fetal  
Small cell undifferentiated 
Macrotrabecular 
 
Mixed epithelial/mesenchymal HB 
With teratoid features 




2.1.3 Genetics and cytogenetics of hepatoblastoma 
 
Although HB pathobiology is still relatively unknown, new molecular mechanisms 
are constantly emerging as the new sequencing methods have become more accessible 
and revolutionised the area of cancer genomics and molecular biology. The most 
common known genetic mutations, altered pathways, and karyotypic changes in HBs 
are listed in Table 3. 
 
The fetal origin of HBs is evident in the gene expression profile of hepatoblasts. 
Variety of growth factor signaling pathways and developmental pathways are 
connected to HB pathogenesis. HB cells produce AFP, a glycoprotein normally 
synthesized by the fetal yolk sac and liver. Majority of HB tumors express hepatic 
progenitor cell markers, including stem cell epithelial adhesion molecule EpCAM, 
hepatoblast and cholangiocyte marker CK19, and EGF-like protein DLK-1, which 
activates the Notch pathway in fetal liver cells (42).  Downregulation of genes 
important in typical liver functions, like fatty acid and xenobiotic metabolics, are 
frequent in HB tumors (43). NFE2L2 gene, encoding a transcription factor that 
activates the cellular antioxidant response to fight xenobiotics and oxidative stress, is 
mutated in approximately 10% of of HBs (44). 
 
The hallmark molecular event in HB pathogenesis is mutation in the canonical Wnt/β-
catenin signaling pathway. A mutation of the CTNNB1 gene (encoding β-catenin) is 
present in approximately 80% of HB tumors (43, 45), but mutations in other 
components of the pathway, including APC, AXIN, and LEF1 are also common (38, 
43, 46, 47). Mutations of β-catenin prevent its normal degradation in the cytoplasm, 
and β-catenin is transferred to nucleus where it activates the transcription of the Wnt 
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target genes, preventing apoptosis and differentiation (48). One of these genes is the 
C-MYC proto-oncogene (MYC), which plays a role in cell cycle progression, apoptosis 
and cellular transformation (49). Activation of MYC signaling has been connected to 
poorly differentiated and highly proliferative HB subclass (50).  
 
Processes involved in cell cycle regulation and proliferation are shown to play 
important role in HB pathogenesis. Mutations and downregulation of oncogenes PLK1 
and P53 controlling the cell cycle have been reported (47, 52). Furthermore, 
hypermethylation of SOCS1 gene, an inhibitor of the JAK/STAT signaling pathway 
affecting cell proliferation, apoptosis, and differentiation, is common in these tumors 
(53). The expression of pro-apoptotic members of BCL2 family is frequently 
downregulated in HBs, whereas the anti-apoptotic, prosurvival members are 
upregulated (54, 55). 
 
Abnormalities in karyotype are common in HBs. The cytogenetic changes are usually 
acquisition (chromosomes 2, 8, and 20) or loss (chromosome 18) of whole 
chromosomes, often occurring in conjunction with structural translocations (27, 56). 
The exact mechanism by which the cytogenetic abnormalities contribute to 
tumorigenesis or their prognostic significance is still relatively unknown (27).  
 
Table 3. Major known mutations, differentially expressed pathways and karyotypic 
changes in HB tumors. Modified from (51). 
 
 
HB genetics and cytogenetics 





Other genes and pathways 






Gains: chr 2, 1q, 8, 6, 12, 17, 20 








The first symptoms of HB are a palpaple mass, abdominal distension, and pain. 
Generalized fatigue, jaundice, and growth retardation are often present. Serum AFP is 
commonly elevated, being the most important marker for diagnosis and follow-up. 
However, 5-10% of HB patients have normal or very low AFP, which is connected to 
poor prognosis (57). Other serum markers, like DLK1 and Glypican3 have been 
suggested for HB, but are not currently in clinical use. Imaging of the tumor size, 
localization, and distribution is performed with ultrasonography (US), computer 
tomography (CT) or magnetic resonance imaging (MRI). US-guided core needle 
biopsy from the tumor is histologically assessed to confirm the diagnosis and subtype 
of the tumor [reviewed in (58)]. 
2.1.5 Staging and prognosis  
 
HB stage and risk level is preoperatively evaluated based on radiological tumor extent 
(PRETEXT) staging system, developed by the Childhood Liver Tumor Study Group 
of the International Society of Pediatric Oncology (SIOPEL) (59). The liver is divided 
into four anatomical segments by hepatic veins and the portal vein; left lateral 
(segments 2 and 3), left medial (segments 4a and 4b), right anterior (segments 5 and 
8) and right posterior (segments 6 and 7). PRETEXT 1-3 are localized tumors with 
high AFP and categorized as the standard-risk tumors. Tumors involving all four 
hepatic sections (PRETEXT 4), and patients with <100ng/mL serum AFP (reflecting 
the SCUD histological subtype), belong to the high-risk group. Very high-risk group 
patients have distant metastases of HB, usually in the lungs, at diagnosis (60). 
PRETEXT is based on the tumor distribution, but also the assessment of histological 
subtype (61), and resectability of the tumor (58) are important factors in the final 
prognosis. The overall 3-year survival rate for standard-risk HB is 91% and for high-
risk HB 53% (59). 
2.1.6 Treatment 
 
The outcome of HB has dramatically improved during the past decades due to 
effective cisplatin and doxorubicin (Dox) -based neoadjuvant chemotherapy (62). 
Cisplatin monotherapy is used for standard-risk patients (63) and combination of 
cisplatin and Dox (PLADO) is used for high-risk patients (64) [reviewed in (65)]. 
After tumor shrinkage with chemotherapy, it is surgically resected. If resection is not 
anatomically possible, yet no extrahepatic metastases exist, a liver transplantation is 
performed (58).  
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2.2 Biliary atresia 
2.2.1 Insidence and etiology 
 
Biliary atresia (BA) is a rare idiopathic disorder of the neonates with an obstructive 
fibroinflammatory process obliterating the extrahepatic bile ducts, resulting in 
cholestasis and progressive fibrosis. If untreated, BA leads to cirrhosis and death 
before the age of 2 years. The incidence varies geographically, being highest in East 
Asia (1.5 per 10 000), and 0.5-0.8 per 10 000 in Europe (66, 67). The incidence in 
Finland is 0.54 per 10 000 (68). 
 
About 20% of BA cases are associated with congenital malformations, most 
commonly splenic malformations, vascular malformations, or malrotation (69, 70). 
They are often referred to as “embryonic” form of BA, since they are hypothesized to 
arise during development of laterality during early gestation (71). This theory has not, 
however, been scientifically proven, and there most likely exist several 
etiopathogenetic explanations also in this group of BA (72).  
 
The pathogenetic process of isolated BA without other malformations is thought to 
initiate closer to birth. The exact molecular mechanisms and perinatal events that 
trigger the sclerosing inflammatory process, are widely unknown. Majority of BA 
cases are sporadic. It has also been suggested that viral infections, immune-mediated 
injury, genetic causes, exposure to toxins, or defects in prenatal circulation might 
cause this disease (71, 73).  
 
BA is grouped into three main types according to the extent of fibrosis in the 
extrahepatic bile ducts. Type I atresia involves the common bile duct, type II extends 
up to the common hepatic duct, and type III atresia involves also the porta hepatic and 
thus encompasses all extrahepatic bile ducts. Type III is the most common subclass 
and accounts for over 90% of all BA cases (74). 
2.2.2 Pathobiology  
2.2.2.1 Genetic mutations and alterations in gene expression 
Polymorphism or mutations of genes regulating bile duct development and 
morphogenesis are suggested to predispose to BA. Notch signaling is crucial for the 
initiation of the biliary lineage determination of hepatoblasts and duct morphogenesis 
(75). Abnormal Notch signaling, especially alterations in JAGGED1 and HES1 
expression, is connected to pathogenesis of BA (76-78). Hepatic nuclear factors 
HNF1β and HNF6 are required for early development of the biliary tree, and mice 
bearing mutations in these genes have anomalies and atresia of extrahepatic bile ducts 
(79-81).   
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Aberrant hepatic Hedgehog signaling has been indicated in BA, and suggested to 
induce the epithelial-mesenchymal transition and expansion of cholangiocytes (82). 
Mutations in or reduced expression of Glypican-1 (GPC1) gene, regulator of 
Hedgehog signaling and inflammation, are demonstrated in some BA patients, and a 
zebrafish model reinforces the role of GPC1 in normal development and function of 
biliary tracts (83). 
Abnormal expression of genes associated with left-right patterning, e.g. Inversin 
(INVS) and Cryptic Family 1 (CFC1), are also connected to BA in animal models (84, 
85). This theory is consistent with the observation that the embryonal/fetal form of 
BA is often related to laterality defects causing also accompanying developmental 
anomalies in other organs.  
2.2.2.2 Histological changes 
Ductular reaction (DR) is a dynamic system of expanding bile duct-like cells, 
accompanied by mesenchymal and inflammatory cells, driving the fibrogenesis of BA 
liver (86). The origin of the epithelial cell type of the DR is controversial. The majority 
of these cells derive from proliferating cholangiocytes, but cholestasis also triggers 
metaplasia of periportal hepatocytes towards a cholangiocyte-like phenotype, as an 
adaptive injury escape mechanism (87-89). Furthermore, hepatic progenitor cells 
(HPCs), located in the canals of Hering, are capable of differentiating to either 
cholangiocytes or hepatocytes, and participate in DR by producing reactive 
intermediate hepatocyte- or duct-like cells [reviewed in (90)]. The cells in DR area 
have paracrine communications with myofibroblasts, inflammatory cells and 
endothelial cells, leading to an epithelial-mesenchymal transition and subsequent 
fibrosis [reviewed in (91)].    
The progressive fibrosis, starting from periportal areas, leads to portal hypertension 
and liver cirrhosis in BA. The fibrosis typically forms bridges within and adjacent to 
DR areas of the BA liver. The cellular origin of the fibrosis and extracellular matrix 
production is not clear and it is likely that many cell types of the liver participate in 
this process. Both hepatocytes and cholangiocytes are shown to contribute to the 
fibrosis by epithelial-mesenchymal transition (EMT) (82, 92). Furthermore, 
transdifferentiation of hepatic stellate cells to myofibroblasts has also been 
demonstrated (93). Additionally, HPCs are likely to participate in the process of ECM 
deposition, but their role in the development of fibrosis remains unclear (94). Mavila 
et al. demonstrated an expansion of a cell population that expresses stem cell marker 
prominin-1. The proliferation of these collagen-producing cells was associated with 
activation of fibroblast growth factor (FGF) and transforming growth factor-beta 
(TGFβ) signaling pathway, which in turn are inducers of EMT and fibrosis (95). All 
in all, a complex crosstalk among cholangiocytes, hepatocytes, progenitor cells, 
myofibroblasts, endothelial, and inflammatory cells is required for the onset of DR 
and the subsequent periportal fibrosis in BA. 
REVIEW OF THE LITERATURE 
 25 
2.2.3 Diagnosis  
 
Typical symptoms at the time of diagnosis are jaundice, acholic stools, dark urine, and 
sometimes hepatomegaly in an otherwise healthy and thriving newborn. Coexistence 
of other malformations can cause additional symptoms. BA patients typically have 
conjugated bilirubinemia, as well as elevated gamma-glutamyl transferase, alkaline 
phosphatase, and total serum bile acids, as a result of cholestasis. A common serum 
marker of hepatocellular injury, alanine aminotransferase, is usually only moderately 
elevated at diagnosis.  
 
Radiological examinations are essential for BA diagnostics. In abdominal 
ultrasonography, gallbladder does not visualize in 4/5 of cases and a “triangular cord 
sign” of the hilar structures is often present. Gamma biligraphy shows the 
accumulation of the radioactive label in the liver and very little or no access to 
intestine. Percutaneous needle biopsy presents typical histological changes, including 
cholestasis, ductular reaction (DR), portal inflammation, and fibrosis. The definitive 
diagnosis is established by intraoperative cholangiography which also reveals the level 
of obstruction (71) . 
2.2.4 Treatment and follow-up 
 
BA is surgically managed using the Kasai portoenterostomy (PE) operation, named 
by a Japanese surgeon Morio Kasai, who developed the operation method in the 1950s. 
In the operation, the gallbladder and biliary remnants are removed, and the porta 
hepatis is anastomosed to the bowel in a Roux-en-Y fashion. An early diagnosis and 
undelayed treatment are predictive for a better prognosis (96). In addition, 
postoperative adjuvant therapy including steroids, ursodeoxycholic acid, and 
prophylactic antibiotics seems to improve the clearance of jaundice and native liver 
survival rates (97-99).  
 
In Finland, the diagnostic protocol, surgical care, postoperative treatment, and follow-
up of BA patients were standardized in 2005 when BA management was centralized 
to Helsinki University Hospital by a governmental decision (68). All patients are 
currently administered steroids, ursodeoxyxholic acid, and antibiotics postoperatively. 
Abdominal ultrasonography and liver biochemistry are monitored at regular follow-
up visits, and upper GI endoscopies are performed annually to screen for the 
development of esophageal varices. In addition, routine follow-up liver biopsies are 
taken 1, 5, and 10 years after PE (68).  
 
If the PE operation is not successful (bilirubin remains elevated) or when the slowly 
progressing liver damage either progresses to end-stage liver disease or causes other 
life-threating complications, the treatment is liver transplantation. BA is the most 
frequent indication for liver transplantation among children. Compared to other 
pediatric surgeries, the PE operation relatively often fails in its objective regardless of 
the operator and other circumstances. A recent meta-analysis of five large studies (US, 
France, Japan) reports that over 30% of BA patients that underwent PE do not achieve 
any improvement in jaundice and over half the patients are listed for transplantation 
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within a year of the operation (100). In the long term, only ∼20% of BA patients 
survive to adulthood without a liver transplantation (101). The reason for the ongoing 
liver injury after successful clearance of jaundice by PE remains largely unknown and 
is an area of active investigation. Immunological and inflammatory factors have been 
suggested to play a role in this process (102-104). 
2.2.5 Prognosis 
 
In a large French study with 472 BA patients treated with PE and/or liver 
transplantation, the overall five- and 10-year survival rates were 70% and 68%, 
respectively. Better prognosis was related with early age at PE, the favorable 
anatomical patterns of BA, the absence of other malformations, and the experience of 
the treatment center (105). After the centralization of BA treatment in Finland, 5-year 
native liver survival increased from 38% to 70%, and 5-year overall survival increased 
from 68% to 94% (106). 
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3 GATA TRANSCRIPTION FACTORS 
 
GATA transcription factors are zinc-finger proteins, which bind to a specific (A/T) 
GATA (A/G) DNA motif and can either activate or repress transcription depending 
on the context (107). There are approximately 7 million GATA motifs in the human 
genome (108). In addition to this consensus GATA binding site, these factors can bind 
to large variety of other DNA motifs. The ability to recognize the alternative motifs 
varies between different GATA factors and enables the differential gene regulation in 
cells expressing several GATA factors (109). Furthermore, post-translational 
modifications and varying interactions with cofactors cause functional diversity 
among these transcription factors. 
The C-terminal domain is required for the DNA binding, whereas the N-terminal 
domain can bind to other parts of DNA or cofactor proteins and may also stabilize the 
DNA binding (110). GATA factors are evolutionary highly conserved and found in 
eukaryotic organisms ranging from mold to vertebrates substantiating their 
fundamental roles in development and gene regulation (111).  
There are six members in the vertebrate family of GATA factors, named in the order 
of their discovery. They are divided into two subfamilies; GATA1/2/3 are mainly 
expressed in the hematopoietic tissues [reviewed in (112)], whereas GATA4/5/6 are 
expressed in endoderm-derived tissues; including heart, lung, gonad, and 
gastrointestinal tract [reviewed in (113)], (Figure 5, Table 4). GATA factors play 
pivotal roles in cellular differentiation and cell-fate specification, cell proliferation and 
movement. Their expression is required for the normal development of various organs 
during gestation. Nevertheless, mutations or altered tissue expression of different 
GATA factors are also connected to many human diseases and neoplasias (Table 4). 
 
Figure 5. Structure and homology of the GATA proteins. All GATA factors have two zinc 
fingers (ZnF) –containing DNA-binding domain. Transactivation domains are located in N- 
and C-terminus. The percentage indicates the homology between the domains of different 
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Table 4. GATA transcription factors in mice and humans.  
 
 Postnatal expression  Phenotype of knockout mice  Human mutations 
GATA1 hematopoietic lineage lethal (E11.5-12.5), erythroid 




GATA2 hematopoietic lineage lethal (E12.5), anemia AML and CML, MDS  
GATA3 CNS, kidney, 
T-lymphocytes 
lethal (E11-E12), CNS 
deformities, internal bleeding 
HDR-syndrome, breast 
cancer, ALL  






hernia, defects in 
testicular development 




female genitourinary defects  
CHD 
GATA6 heart, gonads,  
digestive organs, 








E=embryonic day, DS-AMKL= down syndrome - acute megakaryoplastic leukemia, 
CNS=central nervous system, acute myeloid leukemia, CML=chronic myeloid leukemia, 
HDR=hypoparathyreidism, deafness, and renal dysplasia, ALL=acute lymphoblastic 
leukemia, CDH=congenital heart defect, MDS=myelodysplastic syndrome. References: (5, 
107, 113-119) 
3.1 GATA factors in cancer 
Considering their role as regulators of cell survival and maturation, it is not surprising 
that altered expression or activity of GATA factors is associated with carcinogenesis. 
They are connected to variety of human cancers including leukemia and solid tumors 
of many tissues. They affect the metabolism, proliferation, cell death signaling and 
invasiveness of tumor cells. The activity of GATA factors in tissues can be altered by 
mutation, loss of expression mostly by promoter methylation, overexpression, or 
functional interference by interacting proteins [reviewed in (107, 120)]. The function 
of one GATA factor depends on both the cell type and the context of the promoters 
and may thus be even opposite in different cancers.  
 
GATA1/2/3 are strongly connected to different types of leukemia (121), and GATA3 
plays a role in breast cancer progression (122). GATA4/5/6 are associated e.g. with 
tumors of the gastrointestinal tract, lungs, and ovaries. The expression of GATA4 and 
GATA6 is altered in several endocrine-related tumors including ovarian granulosa cell 
tumors, adrenocortical tumors, and pancreatic tumors [reviewed in (118)].  
In gastrointestinal malignancies, GATA4 gene is amplified in a substantial part of 
esophageal adenocarcinomas (123). GATA6 is frequently elevated and suggested to 
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act as oncogene in pancreatobiliary neoplasms (124, 125). GATA6 is shown to 
promote invasion and metastasis of colon cancer (126, 127). There are no previous 
reports about the expression or function of GATA factors in HBs. 
 
In line with their pivotal role in organogenesis, GATA factors affect important 
developmental signaling pathways, like TGFβ and WNT/β-catenin pathways (128, 
129), also connected to oncogenesis in many organs. For instance, GATA4 regulates 
components of TGFβ pathway in adrenocortical tumors (128, 130). Furthermore, 
GATA factors are important regulators of cell growth, proliferation and survival 
during gestation. Accordingly, GATA4 is shown to inhibit apoptotic pathways and 
cell cycle regulation in ovarian granulosa cell tumors (131, 132), where high level of 
GATA4 expression is connected to clinically poor prognosis (133).  
3.2 Expression and function of GATA4 and GATA6 
GATA4 and GATA6 are master regulators of endoderm formation demonstrated with 
mouse embryonic stems cells which differentiate into extra-embryonic endoderm 
when either of these factors is overexpressed (134).  
 
GATA4 gene is located in the short arm of chromosome 8. Gata4 was first cloned and 
characterized in mouse in 1993 by Arceci et al. (135), and it is expressed in the heart 
(136, 137), proximal parts of the gastrointestinal tract (138), lungs (139), and gonads 
(140, 141). Mice null for Gata4 die during embryogenesis at E7.0-E9.0 for heart 
defects and point mutations in GATA4 cause congenital cardiac septal defects in 
humans (136, 142). GATA4 is required for the migration and folding morphogenesis 
of the precardiogenic mesodermal cells, and for regulation of carciac angiogenesis 
(136, 143). GATA4 has an important role in the regulation of gonadal gene expression 
and sex development (144, 145). 
 
In addition to binding DNA, GATA factors interact with cofactors and other 
transcription factors. GATA4 interacts with a transcriptional modifying protein, 
Friend of GATA 2 (FOG2), predominantly expressed in heart, gonads, and brain 
(146). GATA4 binds to FOG2 with its N-terminal zinc-finger (147). Presence of 
FOG2 is essential for the function of GATA4 in heart morphogenesis, and Fog2-/- 
mouse embryos die in midgestation due to cardiac defects (148). 
 
GATA6, cloned in human in 1996 by Suzuki et al. (149), maps in the long arm of 
chromosome 18 and has an overlapping expression profile with GATA4. GATA6 is 
expressed in gastrointestinal tract (138), heart (150), lungs (151), gonads (140, 141), 
and adrenal gland (152). The cells of murine Gata6-/- embryonic ectoderm undergo 
apoptosis shortly after the Gata6 onset in the wild type embryos, and thus Gata6-null 
mice die at E6.5-E7.5 (153). This is partly due to downregulation of transcription 
factor Hnf4, a direct downstream target of GATA6 in visceral edoderm, required for 
the normal gastrulation (153, 154). GATA6 is required for the vascular development 
and expressed in the vascular smooth muscle cells during embryogenesis and 
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postnatally (150). In the developing gonads, GATA4 and GATA6 have overlapping 
but distinct expression patterns, suggesting some functional redundancy (140, 141). 
3.2.1 GATA4 and GATA6 in the liver  
 
GATA4 and GATA6 are expressed in murine foregut endoderm and are both essential 
for the normal development of the liver (155). GATA4 and GATA6 belong to the 
pioneer factors that determine which cells of the endoderm become hepatoblasts by 
modulating the chromatin structure (156, 157). GATA4 potents the hepatic gene 
expression in the primary liver bud. It binds to Albumin (Alb) enhancer before the 
onset of Alb expression in the developing liver (157). The crucial role for Gata4 and 
Gata6 is shown also in early zebrafish liver development, where these factors are 
shown to have functional redundancy in the onset of hepatic development, but 
independent roles in regulating liver organ development (158).  
 
Tetraploid embryo complementation studies (providing Gata4-/- or Gata6-/- embryos 
with Gata4+/+ or Gata6+/+ extraembryonic endoderm) have enabled the generation of 
post-gastrulation stage embryos of homozygote knockout mice (5, 116). These studies 
demonstrate abnormal formation of the liver bud and expression of normal hepatocyte 
markers at E9.5 in both Gata4-/- and Gata6-/- embryos. As GATA4 expression is 
diminished in the liver diverticulum already at this stage, the defect in liver 
development is likely caused by lack of Gata4-mediated signaling from adjacent 
septum transversum. GATA6 in contrary, is present in hepatoblasts at E14.5 (155) and 
is suggested to have a more cell-autonomous role in liver bud expansion (5). 
In human liver, GATA4 is expressed in hepatocytes at gestational week 8, whereas in 
normal postnatal liver, GATA4 is expressed mainly in sinusoidal endothelial cells and 
Kupffer cells (159). There are contradictory reports about the normal expression of 
GATA4 and GATA6 in postnatal murine hepatocytes (160-162). There are no 
comprehensive studies about GATA6 expression in normal human liver.  
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AIMS OF THE STUDY 
This doctoral thesis focuses on the role of GATA transcription factors in HB and BA 
pathogenesis. 
 
The specific aims of the presented research are: 
 
1. To assess the expression and tissue localization of GATA4 and GATA6 in 
normal liver versus HB and BA 
 
2. To clarify the effect of GATA4 gene silencing on the function and gene 
expression of a human HB cell line, focusing on apoptosis and epithelial-
mesenchymal transition 
 
3. To explore the role of GATA6 in ductal metaplasia of hepatocytes in BA
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MATERIALS AND METHODS 
1  Patients and clinical data (I, III, IV) 
HB and BA patients included in this study were treated in Children’s Hospital, 
Helsinki University Hospital during years 1986-2015. Clinical data was obtained from 
patient medical records. 
2 Tissue samples (I, III, IV) 
The use of the patient samples and medical records in this study was approved by the 
Ethical Committee of Helsinki University Hospital (approval number: 
98/13/03/03/2013) and by the Finnish National Authority of Medicolegal Affairs and 
Health (approval number: THL/1239/5.05.01/2015).  All animal experiments were 
approved by the Institutional Animal Care and Use Committee in accordance with the 
National Research Council’s (NRC) Guide for Care and Use of Laboratory Animals. 
2.1  Human tissue (I, III, IV) 
 
Paraffinized human tissue samples were obtained from Helsinki University Hospital’s 
archives of pathology. Postnatal control samples were obtained from healthy organ 
donors and fetal control samples were obtained from obductions. Fresh frozen tissue 
samples from BA, and control livers was also utilized. 
2.2 Mouse tissue (IV) 
 
Mouse tissue samples were obtained from collaboration laboratory in Cincinnati 
Children’s Hospital Medical Center, USA. Two mouse models affecting the biliary 
tree development or function, mimicking cholestatic liver disease were used; surgical 
bile duct ligation model and a genetic model for induced ductular reaction (a liver-
specific double knockout for Hnf6 and Rbpj genes). These animal models have been 
previously described (163-165). 
3 Cell culture (I, II, III, IV) 
Two immortalized, adherent, human liver cancer cell lines were utilized. Human HB 
cell line HUH6 clone 5 was obtained from Health Science Research Bank (Osaka, JP). 
HUH6 is derived from a mixed epithelial/mesenchymal HB of an Asian 12-month-old 
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male (166). Human cell line HepG2 is derived from a hepatic tumor of a 15-year old 
Caucasian male. This cell line has originally been falsely described as hepatocellular 
carcinoma (167), and later re-characterized as epithelial HB in literature (168). Both 
cell lines were cultured at 37°C in Dulbecco's Modified Eagle's Medium (DMEM) 
(Lonza, Basel, CH) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 
100 units/mL penicillin, and 100 μg/mL streptomycin sulfate. The cell lines were 
regularily tested for mycoplasma contamination (Promokine PCR Mycoplasma test 
kit, Promocell, Germany). 
 
Commercially available primary human hepatocytes were derived from 51-year old 
male (III) and 62-year old female (IV) with a non-hepatic cause of death (Lonza, 
Basel, CH), and cultured in hepatocyte-specific supplemented medium according to 
manufacturer’s instructions (Lonza). 
4 Modification of gene expression in cell cultures 
Three methods were used for transient transfections of HUH6, HepG2, and primary 
human hepatocyte cells. Cells were plated 24 h prior to transfections at a density to 
reach 60-70% confluency. 
4.1 Adenoviral transfections (I) 
 
In HUH6 cells, GATA4 overexpression was mediated with a construct expressing rat 
wild-type GATA4 (169). Dominant negative GATA4 adenovirus, producing a 
GATA4 and repressor domain fusion protein, was utilized to disturb the function of 
endogenous GATA4 (170).  
4.2 Liposome-mediated siRNA transfections (II, III) 
 
Small-interfering RNA (siRNA) was used to disturb the transcription and subsequent 
knockdown GATA4 expression. A pool of four siRNAs targeting GATA4 or a non-
targeting (NT) control siRNA were subjected to cells using RNA iMAX 
Lipofectamine reagent in Opti-MEM medium (both from Life Technologies, 
Carlsbad, NY) in the absence of antibiotics. The final siRNA concentration was 
0.1μM.  
4.3 Liposome-mediated plasmid transfections (III, IV) 
 
Cells were transfected with either pMT2-GATA4 expression plasmid (135), pcDNA3-
GATA6 expression plasmid (150), or corresponding control plasmid. Optimem 
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medium and jetPEI™Hepatocyte DNA transfection reagent (Polyplus Transfection, 
Illkirch, FR) for human primary hepatocytes or Lipofectamine LTX with Plus™ 
Reagent (Thermo Fischer Scientific, MA, USA) for HUH6 and HepG2 cells was used 
to perform the transfections.  
5 RNA expression 
5.1 RNA extraction and Real-time quantitative PCR (II, III, IV) 
 
RNA was isolated [Nucleospin RNA/protein kit, Machrey-Nagel, Düren, DE (cell line 
samples) or RNA Easy Mini Kit, Qiagen, Hilden, DE (tissue samples)] and reverse 
transcribed (Reverse transcriptase Core kit, Eurogentec, Liege, BE). qRT-PCR was 
performed using SYBR GREEN (qPCR MasterMix Plus, Eurogentec) and expression 
of gene of interest was normalized to housekeeping genes GAPDH or PPIG (encoding 
cyclophilin G). Primer pairs used are listed in Table 5. 
5.2 RNA microarray hybridization (III) 
 
After 72h of transfection with GATA4 siRNA or non-targeting control siRNA, RNA 
was extracted from two sample sets of HUH6 cells (n=3 in each sample set) and 
purified (NucleoSpin RNA Clean-Up XS kit, Machrey-Nagel). RNA quality was 
assessed with Bioanalyzer (Agilent, CA, USA). All 12 samples were subjected to 
RNA microarray hybridization, performed by the Functional Genomics Unit at the 
University of Helsinki using an Illumina Human HT-12 v4 oligonucleotide expression 
BeadChip (Illumina, CA, USA). Background correction was done on raw array data 
using BeadStudio software (Illumina, San Diego, CA) before quantile normalization 
and log2 transformation were performed using the BeadArray Bioconductor package 
(171). Linear models for microarray data (LIMMA) (172) with Benjamini-Hochberg 
correction were used to identify differentially expressed genes. Expression level 
changes with a false discovery rate (FDR) below 5% were considered as significantly 
differentially expressed. Microarray data was subjected to average linkage clustering 
with uncentered correlation using Cluster (173), and heatmap was generated with R 
(174). GOstats Bioconductor package was used to perform gene set enrichment 
analysis of the differentially expressed genes (175).  
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Table 5. qRT-PCR primers. 
 
Gene Primer sequence 5´→ 3´ Gene  Primer sequence 5´→ 3´ 
ADD3 F: GGCTCTGCGGCGCTTA 
R: CTTGTTATCTCGCAGCGCGT 
GATA4 F: CTCCTCTGCACATTGCTGTT 
R: GTGTGGGGAGGCGTAGTAT 
AFP F: GAGGGAGCGGCTGACATTAT 
R: CATGGCCTCCTGTTGGCATA 
GATA6  F: GTGCCCAGACCACTTGCTAT 
R: TGGAATTATTGCTATTACCAGAGC 






ALB F: GCTGTCATCTCTTGTGGGCTGT 
R: AAACTCATGGGAGCTGCTGGTT 
HNF1β F: GGCCTACGACCGGCAAAAGA 
R: GGGAGACCCCTCGTTGCAAA 
BCLXL F: TCCCCATGGCAGCAGTAAAG 
R: TCCACAAAAGTATCCTGTTCAAAGC 
HNF4α F: TGTCCCGACAGATCACCTC  
R: CACTCAACGAGAACCAGCAG 
BCL2 F: GGATAACGGAGGCTGGGATGC 
R: GCAGAGTCTTCAGAGACAGCC 
HNF6 F: TGTGGAAGTGGCTGCAGGA 
R: TGTGAAGACAACCTGGGCT 
BID F: GTCGCCACTGGGACACTG 
R: GGAACCGTTGTTGACCTCAC 
IGFBP1 F: TTTAGCCAAGGCACAGGAGA 
R: ATGGATGTCTCACACTGTCTGC 
BAD F: TGTGGACTCCTTTAAGAAGGGAC 
R: CACCAGGACTGGAAGACTCG 
JAG1 F: TGCCCTCCAGGACATAGTGG 
R: ACTCTCCCCATGGTGATGCA 
BAX F: TCCCCATGGCAGCAGTAAAG 
R: CAAACAGGCTGGTGGCAATC 
MMP1 F: AGTCCAGAAATACCTGGAAAAATA  
R: TTTTTCAACCACTGGGCCAC 
BAK F: TCATCGGGGACGACATCAAC 
R: CAAACAGGCTGGTGGCAATC 
MSF  F: CCCATCCAGTGGAATGCACC 
R: GGTGGGATACTCACAGGTCT 
BCLW F: CTTTGTCTTTGGGGCTGCAC 
R: CTGTGAACTCCGCCCAGC 
NOTCH2 F: GGCATTAATCGCTACAGTTGTGTC 
R: GGAGGCACACTCATCAATGTC 
BMP4 F: CTGCGGGACTTCGAGGCGACACTTCT 
R: TCTTCCTCCTCCTCCTCCCCAGACTG 
PPIG F: CAATGGCCAACAGAGGGAAG 
R: CCAAAAACAACATGATGCCCA 
CDH1 F: CACCACGGGCTTGGATTTTG 
R: TGGGGGCTTCATTCACATCC 
RHOB F: GTGTGTCTGTTCGACTCCCC 
R: AGGGATATCAAGCTCCCGCT 
CDH2 F: GCGTCTGTAGAGGCTTCTGG 
R: GCAGTTGCTAAACTTCACATTGAG 
RHOU F: TGCCGGACAGGATGAATTTGA  
R: TGGGACAGTGGCATCGAATC 
CK19 F: CTGCGGGACAAGATTCTTGGT 
R: CCAGACGGGCATTGTCGAT 
SRC F: CAGATTGTCAACAACACAGAGGG 
R: CACGTAGTTGCTGGGGATGT 
COL4A2 F: GGATGGCTATCAAGGGCCTG 
R: CTGGCACCTTTTGCTAGGGA
SMAD5 F: CTATGTTGGAGAGGTGTATG 
R: CAGCACGTGGTGGGATGAAA 
CTNNB1 F: ATTGAAGCTGAGGGAGCCAC 
R: TGCATATGTCGCCACACCTT 
SOX9 F: GTACCCGCACTTGCACAAC 
R: TCTCGCTCTCGTTCAGAAGTC 
DKK1 F: TCACACCAAAGGACAAGAAGG 
R: ATCTTGGACCAGAAGTGTCTAGC 
SYTL2 F: AGTGAAGGCTCGCAACGC 
R: CACCTACCTCCGAGTCGCT 
DOCK8 F: GACCCTAGAAGCCACCGAAC  
R: TCCGCTGAAGAATACCTGTTGA 
TIMP2 F: CAGATGTAGTGATCAGGGCCAA  
R: CCTTCTCAGGCCCTTTGAACA 
GAPDH F: GGTCATCCATGACAACTTTGG  
R: CCATCCACAGTCTTCTGGGT 
TAT F: GGGGACCCTACTGTGTTTGG 
R: ACTGGATAGGAAGCCGATGG 
 
5.3 RNA in situ hybridization (III, IV) 
 
Formalin-fixed paraffin embedded (FFPE) tissue sections (thickness 5 µm) were 
subjected to RNA in situ hybridization using RNAscope 2.5 HD detection kit-RED 
(#322350, ACDBio, Milano, IT) for chromogenic target mRNA detection and 
RNAscope Multiplex Fluorescent Reagent Kit Version 2 (#323100, ACDBio) for 
fluorescent target detection. After baking for 1 h at 60°C, tissue sections were 
deparaffinized and treated with hydrogen peroxide for 10 min at RT. Target retrieval 
was performed for 15 min at 97°C, followed by protease treatment for 15 min at 40°C. 
The probes were hybridized for 2 h at 40°C followed by signal amplification. For 
chromogenic detection, the samples were incubated for 45 min with AMP 5–RED 
reagent. The samples were then treated with fast red for 10 min at room temperature 
followed by counterstaining with 50% hematoxylin.  
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For fluorescent detection, Signal amplification and development for HRP channels 
were performed according to the manual. TSA Plus Cyanine 3 fluorophore 
(NEL744001KT, Perkin Elmer), and TSA Plus Cyanine 5 fluorophore 
(NEL745001KT) were used used at 1:1500 dilutions for different probes. The sections 
were counterstained with DAPI.  Probes used for ISH are listed in Table 6. 
 
 
Table 6. RNA in situ hybridization probes. 
 
Gene Probe ID# Article 
JAG1 546181 IV 
HNF6 490081 IV 
HNF1β 490071 IV 
GATA6 603131 IV 
GATA4 579821 III 
CK7 550151 IV 
CFTR 603291 IV 
 
6 Protein expression 
6.1 Protein extraction and western blotting (I, II, IV) 
 
Protein was isolated from cell culture lysates and tissue samples using Nucleospin 
RNA/Protein kit (Machrey-Nagel), separated by weight with 7.5% SDS-PAGE, and 
transferred onto a PVDF membrane (Invitrogen, CA, USA). Nonfat 5% milk in 0.1% 
Tween-TBS was used to block unspecific binding. Primary antibodies were incubated 
o/n at 4°C and secondary antibodies were incubated for 1h at RT. Proteins were 
visualised with Enhanced Chemiluminescence Prime kit (G&E healthcare, IL, USA). 
β-Actin or GAPDH were used as loading controls. The primary and secondary 
antibodies used are listed in Table 7. 
6.2 Immunoperoxidase and immunofluorescence stainings (I, III, IV) 
 
FFPE liver sections were deparaffinized, hydrated, and treated with 10 mM citric acid 
in 97°C for 20 min or Target retrieval solution for 35 min (Dako, Glostrup, DK). 
Endogenous peroxidase activity was blocked with 3% H2O2, and nonspecific binding 
was prevented by using 1.5% normal serum. Immunoperoxidase staining was 
performed using a polymerized reporter enzyme staining system (ImmPRESS reagent 
kit; Vector Laboratories, Burlingame, CA or Novolink Polymer Detection System; 
Leica Biosystems, Newcastle, GB) to visualize the bound antibody. Primary 
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antibodies, listed in Table 7, were incubated overnight at 4°C. In control experiments, 
nonimmune serum replaced the primary antibody. Sections were counterstained with 
hematoxylin.  
 
For immunocytochemistry, HUH6 cells were cultured in Matrigel coated Nunc 
LabTek 2-well chamber slide systems (Thermo Scientific, Waltham, MA). Cells were 
fixed and permeabilized in 100% methanol. Unspecific binding was blocked with 
UltraVision Protein Block (Thermo Scientific). Cells were incubated in primary 
antibody for 1h at RT (listed in Table 7).  
 
Images were collected using 3DHISTECH Panoramic 250 FLASH II digital slide 
scanner at Genome Biology Unit (Research Programs Unit, Faculty of Medicine, 
University of Helsinki, Biocenter Finland). 
 
Table 7. Primary antibodies used in this study. 
 
Antigen Species Reference# Method (dilution) Article 
β-actin goat SC-1616 WB (1:10 000) I,II 
BCL2 mouse MO887 WB (1:500) II 
BCLXL rabbit 2762S WB (1:500) II 
BID mouse SC-373939 WB (1:500)  
Cytokeratin 7 rabbit SP52 IHC (1:1000) IV 
E-cadherin mouse  IF (1:200) III 
Erythropoietin rabbit SC-7956 IHC (1:100) I 





goat SC-1237 IHC (1:200), WB (1:1000) I, II 
GATA6 (human) rabbit SC-9055 IHC (1:1200), ICC (1:200) I,IV 
GATA6 
(human/mouse) 
goat AF1700 IHC (1:1200), WB (1:1000) IV 
Ki-67 mouse SC-15402 IHC (1:200) I 
N-cadherin mouse  IF (1:50) III 
 
7 Apoptosis, proliferation, and cell viability assays (II) 
Apoptosis was analysed from HUH6 cells with Caspace-Glo 3/7 luminescent Assay 
(Promega, Madison, WI, USA), measuring the activity of apoptosis effector caspaces 
3 and 7. Luminometer (Lab systems Luminoskan RS, Helsinki, Finland) was used to 
detect the luminescence levels. Cell proliferation was assessed by BrdU Assay 
(Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instructions. The assay 
measures incorporation of a thymidine analog, into the newly synthesised DNA of 
proliferating cells. Cell viability was measured with WST-1 assay (Roche, Basel, CH), 
based on the level of mitochondrial enzymes present in viable cells. Colorimetric 
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BrdU and WST-1 assays were analyzed with a spectrophotometer (Multiskan EX, 
Thermo Scientific, MA, USA). 
8 Migration assays (III) 
For wound healing assay, HUH6 cells were cultured for 24h on a collagen I–coated 
plates. A scratch was created in the confluent cell monolayer and images were 
captured in the beginning (0h) and after 24h. Remainder of migrating cell area from 
the two timepoints was calculated. 
 
For transwell migration assay, a suspension of 6x104 HUH6 cells was applied to 8µm-
pore inserts, with the bottom of the insert coated with collagen I. Serum-free media 
was applied in the upper chamber, and normal growth media in the lower chamber. 
Cells were allowed to migrate for 40 hours, after which the cells were fixed with 4% 
PFA and stained with crystal violet. The number of migrated cells was manually 
counted under light microscope from 5 fields per well.  
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RESULTS AND DISCUSSION 
1 GATA4 IN HEPATOBLASTOMA PATHOGENESIS (I, II, III) 
1.1 GATA4 expression in normal liver and hepatoblastomas (I, III) 
 
Transcription factor GATA4 is expressed in early human fetal liver at gestational week 
(GW) 8 (159). We demonstrated that by GW12 it is mostly restricted to the non-
hepatocyte cell population of the liver (I). Contradictory reports about the expression 
and function of GATA4 in postnatal hepatocytes have been published (159, 160, 162, 
176). We therefore studied the expression levels of GATA4 in livers of healthy organ 
transplant donors with a normal liver histology (n=18). Low or negligible levels of 
GATA4 mRNA and protein were expressed in normal hepatocytes (Figure 6A-B). 
GATA4 protein expression varied to some extent among the liver samples and through 
different areas of the samples, whereas GATA4 mRNA exression remained more 
consistent. Contrary to the findings in hepatocytes, high GATA4 expression was found 
in vena endothelium, sinusoidal endothelial cells, and Kupffer cells in all the samples 
(Figure 6B). 
 
In HB tissue, GATA4 was highly expressed compared to hepatocytes of normal liver 
samples and to the liver parenchyma adjacent to the tumor cell areas in HB samples. 
Especially tumor areas with a distinct embryonal, undifferentiated histology were 
highly positive for GATA4. This high expression of GATA4 was reflected in both 
mRNA and protein levels (Figure 6C-D).  
  




Figure 6. GATA4 expression is absent in normal hepatocytes and high in HB tumor cells. 
A-B: In situ hybridization (A) and immunohistochemistry (B) of GATA4 in normal adult liver 
(NL) demonstrate very low or absent expression of GATA4 in hepatocytes (black arrowhead), 
and high expression in Kupffer cells (arrow).  
C-D: In situ hybridization (C) and immunohistochemistry of GATA4 in an embryonal 
hepatoblastoma (HB) demonstrate abundant GATA4 expression in tumor cells (white 
arrowhead). Red indicates positive signal of GATA4 mRNA and blue indicates positive signal 
of DAPI (A and C). Brown indicates positive signal for GATA4 (B and D).  
1.1.1 GATA4 in HUH6 cell line 
 
In this study, a human HB cell line HUH6 was used as an in vitro model. We found a 
high endogenous GATA4 expression at both mRNA and protein level in this cell line, 
and HUH6 cells were thus well suited for our purpose to study the role and function 
of GATA4 in HBs. An indisputable weakness of this study is the usage of only one 
cell line to model the actions of GATA4 in HBs. This is due to the fact that there are 
only few other HB cell lines established, and some of them are indefinitive as to the 
character or diagnosis of the originating tumor (177). For instance, HepG2 cell line, 
derived from a 15-year-old child with liver tumor, has been commonly referred to as 
hepatocellular carcinoma but recently re-characterized as epithelial HB (168). 
Consistent with this, we found high levels of GATA4 mRNA in HepG2 cells (data not 
shown), and in the planned future experiments, also this cell line will be utilized beside 
HUH6.  
 
The disadvantages of cell lines in general are lacking of the tumor microenvironment 
and loss of their original characteristics during years or growing on plate. An 
interesting and more reliable model to test tumor behavior would be transplantation-
based or genetically engineered (GEMM) mouse models [reviewed in (178)]. Patient-
derived xenograft model where the tumor cells of a patient are transplanted into an 
immunodeficient mouse, are able to recapitulate the original nature and gene 
expression of the tumor cells, and even to develop pulmonary metastasis (179, 180). 
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GEMM mouse models for HB include c-Myc or  mutant β-catenin expressing 
transgenic mice [reviewed in (180)]. 
1.1.2 GATA4 expression in hereditary tyrosinemia type 1 and childhood 
HCCs 
 
To find out if the high GATA4 levels were specific to HBs, we also assessed GATA4 
expression profile in hepatocellular carcinomas (HCC). We found that in contrast to 
HBs, 9/10 of the adult HCCs were negative for GATA4 similar to normal postnatal 
hepatocytes (I). In children, HCC is more uncommon than HB and its incidence 
increases with age. Only 0.5-1% of all childhood liver malignancies are HCCs (26, 
181). Hereditary tyrosinemia type 1 (HTT-I) is a metabolic disorder enriched in 
Finland leading to abnormal liver function and associates with HCC tumorigenesis 
(182). HTT-I is caused by deficiency of the enzyme fumaryl acetoacetate hydrolase 
(183). It ultimately causes liver cirrhosis and increased regeneration of liver tissue; the 
regeneration nodules are preneoplastic and have a high risk of transforming into HCC 
if early liver transplantation is not performed. Interestingly, majority of childhood 
HCCs (chHCC) and HTT-I regeneration nodules, predisposing to HCC tumors, both 
abundantly expressed GATA4 (Figure 7). This reflects the fact that although 
theoretically different cellular origins and etiologies of these tumors, there is a thin red 
line between pediatric HCC and HB, and the histological diagnosis is not always clear.  
 
 
Figure 7. GATA4 expression is high in HTT-I and chHCC.  
Immunohistochemical stainings demonstrate abundant expression of GATA4 in  
A: HTT-I regeneration nodulus and B: childhood HCC tumor. 
Brown indicates positive signal for GATA4 in nuclei. 
 
1.2 Modification of GATA4 level in HUH6 cells (I, II, III) 
 
We hypothesized, that GATA4 is a driver of a malignant phenotype of HB, thus 
providing these neoplastic cells an advantage in growth, survival, or metastasis. For 
assessing the significance of GATA4 in HB cells, modification of GATA4 expression 
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levels in HUH6 cell line was performed, and thereafter the subsequent changes in 
function and gene expression were measured with several methods.  
 
GATA4 was overexpressed in HUH6 cells with a GATA4 wild type (WT) adenovirus 
vector and LacZ vector was used as a control (Figure 8A). However, since HUH6 cells 
readily had a high endogenous expression of GATA4, the primary aim was to 
downregulate it to find significant differences in cell behavior in the absence of 
GATA4. GATA4 function was disturbed by a GATA4 DN adenovirus (I). A flag 
subunit was attached to the GATA4 mutant construct, and as shown in Figure 8B, the 
GATA4 DN was strongly expressed in HUH6 cells. Actual knockdown of GATA4 
down to 20% from the original expression level was reached with siRNA constructs 
(II, III). The silencing of GATA4 was demonstrated at mRNA (Figure 8C) and protein 
(Figure 8D-E) levels. An even more specific and efficient way of gene manipulating 
that could be used in our future studies is the CRISPR Cas9 technology, in which a 
site-specific double strand break in the DNA is created with Cas9 endonuclease to 
silence the gene of interest (184). 
 
GATA4 and GATA6 are shown to have functional redundancy in many tissues (158, 
185). As GATA6 is expressed in untreated HUH6 cells and also in many HB tumors, 
we measured the expression of GATA6 mRNA 72 hours after knockdown of GATA4 
and found that GATA6 levels remained unaltered. It is, however, possible that GATA6 
can take up some functions of GATA4, even though its expression remained constant. 
 
 
Figure 8. Modification of GATA4 
expression in HUH6 cell line. 
A: Western blot (WB) of GATA4 
overexpression with WT virus compared to 
LacZ control virus. β-actin serves as loading 
control in WBs.  
B: Flag protein is detected with WB in the 
cells infected with DN, unlike LacZ control.  
C: Relative expression of GATA4 mRNA 
after treatment with nontarget (NT) siRNA 
and GATA4 (G4) siRNA. **=p<0.01. 
D: WB of GATA4 after siRNA treatment.  
E: Immunofluorescence staining 
demonstrates reduced GATA4 expression 
after G4 siRNA compared to control NT 
siRNA. Blue indicates positive signal of 
DAPI, green indicates positive signal of 
GATA4.
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1.3 Relation of GATA4 to HB cell apoptosis (II) 
 
Apoptosis is a process of programmed cell death, normally activated by a DNA 
damage which is beyond repair. Apoptosis plays an important role in development and 
tissue homeostasis, and its dysregulation leads to many diseases, including cancer 
(186). One hallmark of tumor development is the ability of the cancer cell to escape 
apoptosis. Two apoptotic pathways exist; extrinsic (death receptor pathway) is 
activated when a ligand binds to the death receptor on the cell surface, whereas 
intracellular stimuli can induce apoptosis by releasing mitochondrial cytochrome-c. 
Both pathways trigger the caspace cascade which eventually executes the programmed 
cell death [reviewed in (187)].  
 
The balance of the anti- and proapoptotic B-cell lymphoma-2 (BCL2) protein family 
members determines the threshold of the intrinsic apoptotic pathway [reviewed in 
(188)]. The antiapoptotic members include BCL-2, BCL-XL, BCL-XS, BCL-w, and 
BAG; and the proapoptotic members include BCL-10, BAK, BAX, BID, BIM, BIK, 
and BLK (189). The expression of BCL2 proapoptotic genes is frequently 
downregulated in HBs, whereas the anti-apoptotic, prosurvival genes are upregulated 
(54, 55).  
 
GATA4 regulates the cell survival signaling in other cell types. More specifically, it 
is shown to have an anti-apoptotic role in cardiomyocytes, ovarian granulosa cells, 
lung vascular smooth muscle, and childhood acute lymphoblastic leukemia (140, 190-
192).  
1.3.1 Effects of GATA4 modulation on HB cell viability 
 
Cell viability can be altered by changes in cell proliferation or cell death. In addition 
to apoptosis, programmed cell death can occur through three other pathways: necrosis, 
autophagy, or pyroptosis [reviewed in (193)]. Necrosis and pyroptosis occur mostly 
with presence of pathogens and result to an inflammatory response, autophagic cell 
death has characteristics of both necrosis and apoptosis and is often accompanied by 
other cell death pathways. In this study, we focused on HB cell proliferation and 
apoptosis. 
 
First, the effect of modifying GATA4 expression on baseline viability of HUH6 cells 
was assessed. Although there was a trend towards a reduced viability and increased 
apoptosis (measured by activity of executioner caspases -3 and -7) with siRNA-
mediated silencing of GATA4 (Figure 9A-B) this result did not reach a statistical 
significance. GATA4 overexpression by WT adenovirus did not affect baseline 
proliferation or apoptosis (Figure 9C-D). 
 
 




Figure 9. Cell viability, proliferation, and apoptosis in HUH6 cells after GATA4 
modification. 
A: Relative cell viability of HUH6 cells after NT siRNA or G4 siRNA measured by WST-1 
assay. 
B: Relative apoptosis rate of HUH6 cells after NT siRNA or G4 siRNA measured by caspase 
3/7 assay. 
C: Ratio of proliferating cells to all cells after LacZ or WT adenovirus measured by BrdU 
assay. 
D: Relative apoptosis rate of HUH6 cells after LacZ or WT adenovirus measured by caspase 
3/7 assay. p>0.05 compared to NT or LacZ in all experiments. 
 
 
Since there was no significant difference in the viability of HUH6 cells after silencing 
GATA4, we presumed that high expression of GATA4 benefits HB cells in some other 
way. In ovarian granulosa cell tumors, GATA4 is shown to protect the cancer cells 
from the extrinsic apoptotic pathway induced by TRAIL (TNF-related apoptosis-
inducing ligand) and also to regulate the components of intrinsic apoptotic pathway 
(131, 132). Next, we assessed whether GATA4 has a similar protective role from 
extrinsic inducers of cell death also in HB cells. 
1.3.2 Effects of Doxorubicin on HUH6 cells 
 
Doxorubicin (Dox) is an anthracycline drug commonly used in the treatment of high-
risk HB patients. The main mechanisms of its action are disruption of topoisomerase-
II-mediated DNA repair and generation of free radicals damaging cell components 
[reviewed in (194)]. A well-known side effect of Dox therapy is cardiomyopathy 
(195). Downregulation of GATA4, abundantly expressed in normal cardiomyocytes 
and essential for their function, has been implicated in pathogenesis of Dox-induced 
cardiomyopathy. Dox is shown to suppress GATA4 expression and its DNA-binding 
activity in cardiomyocytes (196-201). Furthermore, silencing GATA4 in these cells 
enhances the Dox-induced autophagy and apoptosis by affecting BCL2 (B-cell 
lymphoma-2) mediated intrinsic pathway (198, 202) (Figure 13).  
 
The expression of BCL2 proapoptotic genes is frequently downregulated in HBs, 
whereas the anti-apoptotic, prosurvival genes are upregulated (54, 55). Since Dox is 
effective for treatment of HB, we hypothesized it may act partially through GATA4 
mediated apoptotic mechanisms also in HB cells. Increasing concentrations of Dox 
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were administered to HUH6 cells and a significant apoptotic response was reached on 
after 48 hours of Dox treatment with a concentration of 100ng/ml (II).  
1.3.3 DOX inhibits GATA4 expression and alters the balance of BCL2 protein 
family  
 
Similar to its actions in cardiomyocytes (198), Dox markedly decreased GATA4 
mRNA and protein levels in HUH6 cells with concentration of 50ng/ml (Figure 10). 
We also measured the effect of Dox on the expression of several BCL2 family 
members (anti-apoptotic BCL2, BCLXL, BCL-W, and pro-apoptotic BAK, BID, BAD, 
BAX) and found a statistically significant decrease in BCL2 and an increase in BAK 





Figure 10. Effects of Dox on GATA4, BCL2, and BAK in HUH6 cells. 
Dox treatment for 48 hours causes downregulation of GATA4 and antiapoptotic BCL2, and 
an upregulation of proapoptotic BAK. *=p<0.05 compared to Dox 0 ng/ml. 
1.3.4 DOX-induced apoptosis is enhanced with GATA4 silencing 
 
To investigate whether the reduction of GATA4 after Dox treatment was causing the 
altered expression of the BCL2 protein family members, we measured their expression 
after siRNA-mediated GATA4 silencing. Two members of the BCL2 family were 
altered, antiapoptotic BCL2 and proapoptotic BID, demonstrated at both mRNA 
(Figure 11A) and protein (Figure 11B) levels. Like the expression changes of BCL2 
and BAK after Dox treatment (1.3.3), also these changes shifted the balance of the 
intrinsic apoptotic pathway towards a proapoptotic direction. 
 
Finally, we measured the cell viability and apoptosis of HUH6 cells after combination 
of GATA4 siRNA (72h) and Dox (48h) treatment. We found a significant difference 
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in both cell viability and apoptosis at concentration 100ng/ml compared to control 





Figure 11.  GATA4 silencing affects the expression of BCL2 and BID, and increases Dox-
induced apoptosis in HUH6 cells. 
A-B: Relative expression of BCL2 is reduced and BID is increased with after GATA4 silencing 
(G4) compared to control (NT), as shown with qPCR (A) and western blotting (B).  β-actin 
serves as loading control.  
C: Relative apoptosis rate after Dox treatment is higher with GATA4 siRNA (G4) compared 
to control siRNA (NT), measured by caspace 3/7 assay. *=p<0.05 compared to NT. 
 
It is not known, whether GATA4 is a direct regulator of BCL2 and BID in HUH6 cells, 
or what other mechanisms and pathways are mediating this effect. Chromatin 
immunoprecipitation (ChIP) studies are needed in the future to clarify the interaction 
of GATA4 and promoters of these genes in HUH6 cells. In cardiomyocytes, GATA4 
is demonstrated to bind GATA site of the BCL2 promoter and positively regulate this 
gene (203). The mode of action of Dox and GATA4 silencing in cardiomyocytes is 
demonstrated in Figure 12A. The present results demonstrate that silencing GATA4 
sensitizes HUH6 cells to Dox-induced apoptosis (Figure 12B). Based on these 
findings, we hypothesize that GATA4 may protect HB cells from Dox also in vivo and 
thus enhance the drug resistance of these tumors. 
  




Figure 12. Schematic figure of sensitizing HUH6 cells to Dox-induced cell death in 
cardiomyocytes vs. HB cells by silencing GATA4.  
A: In cardiomyocytes, Dox decreases GATA4 expression, subsequently leading to 
downregulation of antiapoptotic BCL2 and BCL-XL. These changes promote cardiomyocyte 
autophagy and apoptosis (202, 204). 
B: In HB cells, Dox affects the expression of BCL2 and BAK and downregulates GATA4. 
GATA4 downregulation with siRNA alters the expression of BCL2 and BID. When these two 
are combined, the balance of the BCL2 proteins shifts towards pro-apoptotic and Dox-induced 
apoptosis is enhanced (II). Dox=doxorubicin. 
1.4 The significance of GATA4 in hepatoblastoma migration and 
epithelial-mesenchymal transition (III) 
1.4.1 RNA microarray hybridization of GATA4 silenced HUH6 cells 
 
To unravel the role of GATA4 in HB pathophysiology, a more unbiased approach was 
needed in search for putative target genes and pathways. For this purpose, we 
performed an mRNA microarray hybridization on GATA4 silenced and control HUH6 
cells. We used two sets of samples (n= 3 NT + 3 G4 in each set) and listed the genes 
that were differentially expressed in both sample sets. Purpose of this was to find the 
set of genes that were constantly altered by GATA4 silencing, since HUH6 cells tend 
to differentiate in culture with time. In line with this notion, there was a statistically 
significant difference between the gene expression of the two sample sets of control 
HUH6 cells collected within 14 days of time. The list of overlapping differentially 
expressed genes included 106 genes, from which 79 were upregulated and 34 were 
downregulated (Figure 13).  
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Figure 13. A heatmap of top 50 differentially expressed genes in HUH6 cells after GATA4 
silencing.
Heatmap and two-dimensional clustering of gene expression changes (by adjusted p-values) 
in RNA microarray hybridization of GATA4 silenced (G4) compared to control (NT) HUH6 
cells.  
 
Gene Ontology (GO) analysis (205) was performed on the differentially expressed 
genes to identify biological processes associated with GATA4 inhibition. A 
substantial proportion of the altered genes and biological processes were connected to 
epithelial-mesenchymal transition (EMT) (Table 8). EMT is a gradual process, in 
which the polarized epithelial cell detaches from the basement membrane and adjacent 
cells, obtains enhanced migratory capacity, and produces increased amounts of 
extracellular matrix components. The end point of EMT process is change in cell 
phenotype to a mesenchymal cell, capable of degrading and invasing the basement 
membrane, and migrating from its original site [reviewed in (206)]. Tumor cells 
frequently harness developmental processes and pathways. Accordingly, EMT is 
crucial for normal embryogenesis and organ development, but also a hallmark 
molecular phenomenon in cancer metastasis [reviewed in (207)]. EMT has been 
recognized as an important factor also in hepatocarcinogenesis (208). 
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Table 8. Gene set enrichment analysis of GATA4 silenced HUH6 microarray data. 
 
 
The changes in EMT-related processes were not completely surprising, since previous 
work in Drosophila and MDCK (Madin-Darby canine kidney) cells suggests GATA4 
and GATA6 as conserved repressors of cell epithelial characteristics and as promoters 
of migration and mesenchymal gene expression (209). Another transcription factor, 
HNF4α, promoting hepatocyte lineage differentiation from hepatoblasts, is also 
connected to EMT in HCCs. Loss of HNF4α expression has been demonstrated to 
cause loss of cell polarity, and cell-cell and cell-ECM adhesion in mouse HCC 
xenografts (210). Of interest, HNF4α  has been connected to GATA-factors in 
endoderm development and in HepG2 cell culture experiments (153, 211). 
1.4.2 Altered expression of EMT genes in HUH6 cells after GATA4 silencing 
 
For further analyses, we selected genes related to epithelial-mesenchymal-balance, 
adhesion, migration, and invasion from the list of differentially expressed genes 
(DEGs) in HUH6 RNA microarray and validated the results with qPCR. As the 
microarray sensitivity is relatively low, we also selected some key genes that were not 
significantly altered in the array, but important for EMT or connected to GATA4 in 
other tissues, for qPCR analysis. The altered genes were categorized into three groups 
according to their function: 1) organization of the actin cytoskeleton and migration, 2) 
cell-to-cell adhesion and cadherin switch, 3) remodelling of the extracellular matrix 
(ECM) (Table 9). 
 
 
Biological Process GO ID p-value 
Wound healing GO:0042060 0.0003 
Establishment or maintenance of monopolar cell polarity GO:0061245 0.003 
Tissue morphogenesis GO:0048729 0.004 
Epithelial cell differentiation GO:0030855 0.009 
Positive regulation of substrate-dependent cell migration GO:1904237 0.012 
Establishment or maintenance of bipolar cell polarity GO:0061245 0.018 
Establishment of apical/basal cell polarity GO:0035089 0.023 
Calcium-independent cell-matrix adhesion GO:0007161 0.023 
Protein localization to adherens junction GO:0071896 0.023 
Regulation of endothelial cell migration GO:0010594 0.028 
Planar cell polarity pathway involved in axis elongation  GO:0003402 0.035 
Positive regulation of cell-cell adhesion  GO:2000049 0.041 
Establishment of tissue polarity GO:0007164 0.044 
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Table 9. Altered gene expression of HUH6 cells after GATA4 silencing. 
 
 







1) Cytoskeleton reorganization and migration 
ADD3 0,75 0.0057** 0,73 0.043* 
AHNAK 0,78 0.0007** 0,61 0.015* 
DOCK8 0,97 0.62 0,71 0.033* 
RHOU 0,76 9.61E-05** 0,69 0.002** 
SYTL2 0,66 8.18E-07** 0,48 0.008** 
SRC 0,99 0.45 0,77 0.033* 
RHOB 1,28 0.0023** 1,46 0.034* 
2) Cadherin switch 
CDH1 1,02 0.074 1,47 0.001** 
CDH2 0,95 0.12 0,71 0.045* 
3) ECM remodelling 
MSF 0,64 6.88E-06** 0,57 0.005** 
IGFBP1 0,76 0.0006** 0,51 0.007** 
TIMP2 0,93 0.08 0,88 0.048* 
MMP1 0.99 0.13 0,46 0.030* 
COL4A1 1,32 0.0031** 1,46 0.048* 
 
ADD3=adducin 3, AHNAK=ahnak nucleoprotein, DOCK8=dedicator of cytokinesis 8, RHOU=Ras 
homolog family member U, SYTL2=synaptotagmin like 2, SRC=SRC proto-oncogene, RHOB=Ras 
homolog family member B, CDH1=cadherin 1 (encoding E-cadherin), CDH2=cadherin 2 (encoding 
N-cadherin), FN1-7.3=fibronectin 1 splice variant 7.3 (encoding FN-EDB), IGFBP1=IGF binding 
protein 1, TIMP2=tissue inhibitor of metalloproteinase 2, MMP1=matrix metalloproteinase 1, 
COL4A1=collagen type 4 alpha 1 chain. *P<0.05, **P<0.01. 
1.4.3 GATA4 promotes reorganization of actin cytoskeleton and cadherin 
switch in HB cells 
 
After siRNA mediated silencing of GATA4, a change in the organization of the 
filamentous actin (F-actin) fibers was evident with phalloidin immunostaining. In 
control cells with abundant GATA4 expression, F-actin formed stress fiber bundles in 
cytoplasm enabling cell contraction and movement (Figure 14A). In GATA4 silenced 
cells, F-actin was re-localized mainly in the peripheral parts of the cell, adjacent to 
cell membrane and stress fiber formation was reduced (Figure 14B).  
 
Cadherin switch is a hallmark molecular phenomenon in the EMT process. Epithelial 
E-cadherin is downregulated, and mesenchymal N-cadherin is upregulated, loosening 
the attachment of the cell to adjacent epithelial cells and increasing its migratory 
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capacity (212). Cadherin switch is reported to occur in metastatic HCCs and is 
connected to poor prognosis (213). We demonstrated a reverse cadherin switch when 
GATA4 was downregulated in HUH6 cells, i.e expression of E-cadherin was 
increased after G4 siRNA (Figure 14D) compared to NT siRNA (Figure 14C), 
whereas N-cadherin was decreased after G4 siRNA (Figure 14F) compared to NT 
siRNA (Figure 14E). Of note, GATA4 regulates E-cadherin and N-cadherin 
expression also in other tissues, including MDCK cells and ovarian granulosa cells 





Figure 14.  Changes in F-actin cytoskeleton organization and cadherin localization after 
GATA4 silencing. 
Immunofluorescence stainings of  
A-B: In control HUH6 cells (A), F-actin filaments form stress fibers that enable migration, 
after silencing GATA4 (B), F-actin is located mostly on the cell surface and stress fibers are 
scarce. 
C-D: epithelial-type E-cadherin is increased on cell surface after GATA4 silencing (D) 
compared to control (C).  
E-F: mesenchymal-type N-cadherin is increased on cell surface after GATA4 silencing (F) 
compared to control (E). NT=nontarget siRNA, G4=GATA4 siRNA 
1.4.4 GATA4 promotes migration of HUH6 cells 
 
Although EMT is a recognized hallmark of cancer progression, there are only few 
studies about EMT in HBs. In a recent report, Pei et al. demonstrated that GATA4 
promotes the migration and invasion of HUH6 cells (215). We measured the migration 
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of HUH6 cells after GATA4 silencing with two parallel methods and confirmed that 
cells with less GATA4 migrate significantly slower than control cells (Figure 15). This 
result suggests, that GATA4 is a key factor required for maintaining the migratory 
capacity of HB cells, in the same manner as previously shown in MDCK cells (209). 
Presumably, the specific alterations in gene expression demonstrated above account 






Figure 15. Changes in HUH6 migration after GATA4 silencing. 
A scrach migration assay demonstrates that the area of migrating cells from timepoint 0h to 
24h is 2.6 times (E) larger in NT control cells (A and C) compared to GATA4 silenced (G4) 
cells (B and D). **=p<0.01 compared to NT. The assay was performed in triplicate. 
 
1.4.5 Enforced expression of GATA4 alters gene expression in human 
primary hepatocytes 
 
As GATA4 maintains the migratory and mesenchymal-like gene expression in HB 
cells, the next interesting question is whether GATA4 overexpression is able to initiate 
this gene expression profile in normal hepatocytes. To test this hypothesis, we forced 
the overexpression of GATA4 by plasmid-mediated transfections in primary human 
hepatocyte culture. The baseline expression of GATA4 was very low in primary 
hepatocytes, and the GATA4 expression plasmid led to a 229-fold increase in its 
expression level. The subsequent changes in gene expression in terms of the EMT-
associated genes altered in GATA4 silenced HUH6 cells was assessed with qPCR. The 
majority (10/14) of these same genes were significantly altered in primary hepatocytes 
after GATA4 overexpression (Figure 16). Out of the altered genes, 8/10 were altered 
in opposite direction with GATA4 silenced HUH6 cells, implying that GATA4 can 
change the gene expression profile of hepatocytes to a mesenchymal direction, and 
thus have a role also in cancer initiation. 
 





Figure 16. Changes in gene expression of primary human hepatocytes after forced GATA4 
overexpression. 
Differentially expressed genes were involved in  
A: migration or cytoskeleton reorganization, B: cadherin switch, C: ECM remodulation.  
*P<0.05, **P<0.01, compared to control cells. 
1.5 Summary of the findings in HB (I, II, III)  
 
Our findings of GATA4 acting as an oncogene in HBs contradicts a recent report 
where GATA4 was demonstrated as a tumor suppressor, frequently silenced in HCCs 
(176). GATA4 is a tumor suppressor in many types of cancer, including colorectal, 
esophageal, and lung cancer, where the GATA4 promoter is frequently methylated 
(216-218). On the other hand, high GATA4 expression is associated with poor 
prognosis and malignant behavior of ovarian granulosa cell tumors (131-133). It is 
possible that GATA4 has variant or even opposite roles in different tissues, or even in 
the same tissue during different phases of development or cellular differentiation. 
HCCs are typically tumors of adults or older children, derived from mature 
hepatocytes, with a different etiology than HBs. It is likely that a complex network of 
molecules and pathways is required for the HB tumorigenesis, GATA4 being but a 
small part of the entity.  
 
 
All in all, the present results demonstrate that transcription factor GATA4 is frequently 
overexpressed in HB tumors compared to normal liver. However, it is not known 
whether GATA4 is an “innocent bystander” or plays an actual role in the function, 
growth, or survival of HB cells. In a HB cell line, silencing GATA4 promotes Dox-
induced apoptosis, decreases migration, and shifts their gene expression towards a 
more epithelial type. On the contrary, overexpression of GATA4 in normal 
hepatocytes increases the expression of genes promoting mesenchymal phenotype. 
These results cannot be directly extrapolated to HB tumors in vivo, as immortalised 
cell lines are in many aspects not the ideal disease models. In the future experiments 
of GATA4 in HB pathobiology, other models like patient derived xenografts and 
genetically engineered mouse models might give more reliable answers to these 
questions. 
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2 GATA6 IN BILIARY ATRESIA PATHOGENESIS (IV) 
2.1 GATA6 expression in normal liver and biliary atresia 
 
GATA6 is required for the early murine liver development, and later in gestation it 
colocalizes in cells expressing HNF1α (155, 160) . GATA6 expression is reported also 
in adult mouse and rat hepatocytes, where it activates the fatty acid binding protein 
gene Fabpl in cooperation with GATA4, GATA5 and HNF1α (160, 162). In normal 
postnatal human liver, GATA6 protein expression is shown to be restricted to non-
hepatocyte cell population (127).  
 
To clarify the expression profile of GATA6 in normal human fetal and postnatal liver, 
we performed mRNA in situ hybridization and immunohistochemistry. At gestational 
week (GW) 13, all cells of the liver abundantly expressed GATA6 (Figure 17A). By 
GW 32, GATA6 expression was found in bile duct epithelium, vena endothelium, and 
inflammatory cells of the liver. In adult human liver, the expression pattern was similar 
to the late stage fetal liver, where hepatocytes showed negative or weak signal (Figure 
17B-C) and cells of bile duct epithelium, cholangiocytes, were strongly positive for 
GATA6 mRNA (Figure 17D) and protein (Figure 17C). 
 
The expression of GATA6 in BA differed from that of normal liver. GATA6 mRNA 
and protein were highly expressed in the hepatocytes of BA livers, especially around 
the ductal reactive areas (Figure 17E-F). The expression was strongest in the 
differentiated bile duct epithelium, similar to normal liver. A descendent gradient in 
GATA6 immunoreactivity could be seen in hepatocytes from the portal areas towards 
the central vein.  
 
Double in situ hybridization of GATA6 and cytokeratin 7 (CK7) demonstrates that 
GATA6 expression is not restricted to reactive ductular cells or hepatocytes 
undergoing ductal metaplasia but expressed in vast majority of hepatocytes in BA 
livers (Figure 17F). A similar expression pattern is reported with another transcription 
factor essential for normal cholangiocyte differentiation, SOX9, suggested to play a 
rolein the development of DR. Expression of SOX9 in newly formed ductal reactive 
cells and adjacent hepatocytes correlates to blood markers of  inflammation and liver 
injury, and furthermore with patient age at PE (219).   
2.1.2 GATA6 expression correlates to established prognostic factors of BA 
 
We correlated GATA6 protein expression in BA patients to several histological [bile 
ductule expansion (BDE), fibrosis, periportal inflammation] and clinical (survival 
with native liver, syndromic/nonsyndromic BA, age at PE, blood laboratory values) 
variables. We found a significant correlation to bile ductule expansion rate (visualized 
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by CK7 staining), age at PE, and plasma alanine aminotransferase (p-ALT), a marker 
for hepatocyte injury (IV). Histologically limited BDE and PE at early age are both 




Figure 17. GATA6 is differentially expressed in normal liver and biliary atresia. 
A: GATA6 protein is expressed in fetal liver hepatoblasts at gestational week 13.  
B-C: GATA6 in situ hybridization (B and D) and immunohistochemistry (C) of normal adult 
liver demonstrates positive signal in cholangiocytes and negative hepatocytes. 
E and F: GATA6 protein (E) and mRNA (F) are abundantly expressed in BA hepatocytes in 
addition to its normal expression in cholangiocytes. Dashed line demonstrates the ductal 
reaction area. 
Arrowhead=hepatocyte, arrow=cholangiocyte. Brown indicates positive signal for GATA6 
protein in nuclei. Green indicates positive signal for GATA6 mRNA, red indicates positive 
signal for CK7 mRNA, and blue indicates DAPI staining in the nuclei. Scale bars: 20µm (B 
and D) or 200µm (others). 
2.2 GATA6 expression in mouse models for BA 
 
Several animal models for BA have been developed to study the etiology and 
treatment of this disease [reviewed in (221)]. In this study, we used two mouse models 
to study GATA6 expression which both develop severe cholestasis and DR. 14 days 
after surgical bile duct ligation (BDL) (222), GATA6 was highly expressed in DR 
areas and hepatocytes (Figure 18B). The sham-operated mice had very low GATA6 
immunoreactivity in hepatocytes, but high GATA6 expression in bile duct epithelium, 
in keeping with our findings in normal human postnatal liver (Figure 18A). Another 
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model for DR was the Alb-Cre;Rbpjflox/flox;Hnf6flox/flox mouse [liver-specific double knockout 
(DKO)] (164), which failed to develop the intrahepatic small branches of biliary tree 
at postnatal day (P) 30, and thereafter had a subsequent prominent DR. The bile flow 
is normalized by P120, when the intrahepatic ductules regenerate. The control mice 
(Alb-Cre negative Rbpjflox/flox;Hnf6flox/flox  mice) demonstrated very low or negative GATA6 
mRNA and protein expression at P30 and P120 (Figure 18C and E), whereas DKO 
mice hepatocytes where strongly positive for GATA6 (Figure 18D). By P120, when 
the liver histology was normalized, GATA6 expression in DKO hepatocytes had 
abolished (Figure 18F). Other animal models of BA could be used in future studies to 
confirm these findings; the closest of them to mimic the human disorder is the rhesus 




Figure 18. GATA6 protein expression in two mouse models for BA. 
GATA6 immunohistochemistry in A: sham control mouse liver, B: BDL mouse liver (14 post-
operative days), C: P30 control mouse liver, D: P30 DKO mouse liver, E: P120 control mouse 
liver, F: P120 DKO mouse liver. Arrowhead=hepatocyte, Arrow=cholangiocyte. Brown 
indicates positive staining of GATA6 in nuclei. Scale bar 50µm. 
2.3 GATA6 expression decreases after portoenterostomy operation 
 
PE is a palliative operation in which the bile flow is re-established and cholestasis 
alleviated. A successful PE (i.e. normalized serum bilirubin after operation) leads to 
improvement of the patient clinical parameters, the cholestatic laboratory values, and 
reduction of portal inflammation in liver (224, 225).  
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We measured GATA6 expression in BA follow-up biopsies (BA-post-PE) taken 302-
6887 days after PE. There was a significant reduction in hepatocyte GATA6 
expression after succesful PE. qPCR from whole liver biopsies demonstrates high 
GATA6 expression levels in BA samples compared to normal late fetal liver (FL), 
adult liver (AL), BA-post-PE samples, and other cholestatic neonatal conditions (DC) 
(Figure 19A). To assure that this reduction is not due to decreased amount of DR and 
bile ducts, we localized GATA6 mRNA with in situ hybridization in BA (Figure 19B) 
and BA-post-PE (Figure 19C) samples. We confirmed that in BA samples GATA6 
expression was localized in hepatocytes and was decreased after PE. The 
downregulation of GATA6 after PE was also evident in protein level as shown by WB 





Figure 19. GATA6 expression is diminished after successful PE. 
A: A boxplot of relative GATA6 mRNA expression, as determined by qPCR, in different liver 
sample groups. *=p<0.05, **=p<0.01 as compared to BA group. B: In situ hybridization of 
GATA6 in BA liver. C: In situ hybridization of GATA6 in BA-post-PE liver. Green indicates 
positive signal of GATA6 mRNA, blue indicates positive signal for DAPI in nuclei. Scale bar 
150 µm. D: WB detection of GATA6 protein in different liver sample groups. NBI=normalised 
band intensity. 
2.4 Forced expression of GATA6 in primary human hepatocytes promotes 
hepatocyte-cholangiocyte transdifferentiation 
 
GATA6 is highly expressed in normal cholangiocytes, and GATA6 mutations are 
shown to cause bile duct anomalies, including gallbladder agenesis and biliary atresia 
(226, 227). Therefore, we hypothesized that the elevated GATA6 in BA is related to 
a compensation mechanism of the cholestatic liver to produce new bile ducts. Major 
proportion of the neoductules in BA livers arise from proliferating cholangiocytes, but 
also ductal metaplasia of hepatocytes is shown to contribute to BDE (87, 89).  GATA6 
correlated to the level of BDE in BA patients and is particularly high in hepatocytes 
around the DR areas.  
 
To test our hypothesis of GATA6 as a driver of hepatocyte ductal metaplasia, we used 
two hepatocyte cell models, primary human hepatocytes and HepG2 cell line. 
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Enforced overexpression of GATA6 (mRNA levels approximately 1500-fold) was 
reached with plasmid transfections. Subsequent changes in gene expression were 
analysed with qPCR. In both cell types, we found significant upregulation of 
cholangiocyte lineage markers HNF1β, HNF6, and JAGGED1 (JAG1) (Figure 20). 
This result suggests, that GATA6 promotes the expression of genes required for early 
differentiation of cholangiocytes from hepatoblasts. In primary human hepatocytes, 
also DKK1 and HNF4α were upregulated (Figure 20). DKK1 is an antagonist of the 
Wnt signaling pathway, inhibiting the hepatocyte differentiation of hepatoblasts 
during development and disease, thus driving their lineage determination towards 
cholangiocytes (228, 229). Interestingly, one hepatocyte lineage marker, HNF4α, was 
also significantly upregulated with GATA6 overexpression. GATA6 is known to 





Figure 20. Altered gene expression after enforced expression of GATA6 in primary human 
hepatocytes. 
Ratio of relative mRNA expression (Log) in GATA6 overexpression vs. control primary human 
hepatocytes. Value <0 indicates downregulation and value >0 indicates upregulation of a 
gene after GATA6 overexpression. Cholangiocyte lineage markers on the left side and 
hepatocyte lineage markers on the right side. 
2.5 Expression of HNF1β, HNF6, and JAG1 is elevated in biliary atresia 
 
Finally, we compared the mRNA expression profiles of the three cholangiocyte 
lineage markers altered in both hepatocyte cell models after GATA6 overexpression 
(HNF1β, HNF6, and JAG1) to that of GATA6. We found that, like GATA6, these genes 
are upregulated in BA samples compared to normal liver, and their expression is 
significantly downregulated after PE (Figure 21A-C). HNF1β, HNF6, and Notch 
signaling, are shown to be dysregulated in BA and other biliary diseases (76-80). 
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Mutations in JAG1 are shown to cause Alagille syndrome, characterized by severe 
paucity of the intrahepatic bile ducts (230). GATA4 and GATA6 are shown to 




Figure 21. Expression of HNF1β, HNF6, and JAG1 in different liver sample types. 
Boxplots of relative HNF1β (A), HNF6 (B), or JAG1 (C) mRNA expression, as assessed by 
qPCR, in different liver sample groups. *=p<0.05, **=p<0.01 as compared to BA group.  
 
We assessed the localization of the HNF1β, HNF6, and JAG1 mRNA by in situ 
hybridization in liver samples. In BA samples, mRNA of these genes was expressed 
in both cholangiocytes and hepatocytes, and thus their downregulation after PE is not 
caused solely by reduction of BDE. Their expression in periportal hepatocytes was 
diminished, similar to GATA6 expression. Furthermore, we correlated the mRNA 
expression levels (qPCR) of HNF1β, HNF6, and JAG1 to that of GATA6 in BA and 
BA-post-PE samples, and found a linear correlation between GATA6 and all three 
genes in BA-post-BE samples (IV). This result may indicate that GATA6 regulates 
these genes also in vivo, and thus promotes the pathologic hepatocyte-cholangiocyte 
metaplasia in BA livers.  
 
Taken together, GATA6 is overexpressed in BA hepatocytes, compared to normal 
liver and other neonatal cholestatic conditions. Human GATA6 mutations are 
connected to biliary malformations, suggesting a crucial role for this factor in the 
normal development and function of the biliary tree (226, 227). We hypothesize that 
the elevated GATA6 in BA hepatocytes promotes their ductal metaplasia and thus 
enhances the development of the DR and subsequent liver damage. When the cause of 
the cholestasis is eliminated (successful PE), GATA6 expression together with the 
pathologic changes in histology are reduced. With time, however, vast majority of the 
operated patients develop liver cirrhosis and end up requiring a liver transplantation 
(101). The causes of this ongoing fibrosis, as well as the role of GATA6 in BA 
progression in long term after PE, remain pivotal future questions. The follow-up 
biopsy samples collected from BA patients in Helsinki University Hospital are 
invaluable in unravelling this issue, and they will be utilized in ongoing studies of the 
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CONCLUSIONS AND FUTURE DIRECTIONS 
In this thesis work, we have investigated the pathogenesis of two severe diseases of 
pediatric liver; HB and BA. These two conditions have very different 
pathophysiologies and manifestations, yet both affecting infants and small children. 
These studies focused on the differentiation and gene expression changes of 
hepatocytes and its precursors driven by the two transcription factors crucial for 
normal liver development, GATA4 and GATA6. Figure 22 demonstrates a simplified 
cartoon of the expression and role of GATA4 and GATA6 in transdifferentiation of 
different liver cell types from normal liver to HB and BA.  
 
  
Figure 22. Schematic figure of GATA4 and GATA6 in different cell types of normal liver, 
HB, and BA. Image created using image vectors from Servier Medical Art: 




Point-by-point conclusions and future directions of the study: 
 
1) GATA4 regulates apoptosis and increases drug resistance in HB cells. 
GATA4 is highly expressed in HBs, whereas its expression in normal postnatal 
hepatocytes is low or absent. In HUH6 human HB cell line, GATA4 regulates the 
balance of the BCL2 protein family members and drives them towards an anti-
apoptotic and pro-survival direction. Silencing GATA4 in these cells sensitizes them 
to the apoptotic effects of doxorubicin, a commonly used cytotoxic drug in the 
treatment of HB.  
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2) GATA4 promotes the malignant mesenchymal phenotype of HB cells. 
GATA4 silencing alters the gene expression of HUH6 HB cells towards an epithelial 
phenotype and reduces the migratory capacity in these cells. Altered expression of 
EMT-related genes affecting 1) cytoskeleton reorganization, 2) cadherin swich, and 
3) ECM remodulation was demonstrated after GATA4 silencing in HB cells. Opposite 
changes occurred in cultured primary hepatocytes with GATA4 overexpression, 
suggesting that GATA4 not only maintains this phenotype in HB cells, but may also 
be capable of inducing a mesenchymal-type gene expression when overexpressed in 
normal liver.  
 
Future aspects: More specific knowledge about the gene regulation by GATA4 in 
HBs is required. Chromatin immunoprecipitation studies would identify the direct 
target genes of GATA4 and will be performed on HUH6 cells in the future. On the 
other hand, it is not known which factors upstream regulate the expression of GATA4. 
Recently, microRNA-based therapy targeting the Wnt/β-catenin pathway has been 
proposed for HB treatment (232). Efforts to downregulate GATA4 or disturb its 
function in vivo, would be helpful for the management of this childhood malignancy. 
Of interest, this has previously been successfully done with another GATA factor, 
GATA2, in an in vitro model for prostate cancer (233). In addition to the cell line 
studies, more sophisticated and reliable models with an in vivo tumor 
microenvironment, are required to assess the role of GATA4 in HBs. Comparison of 
patients’ clinical outcome to GATA4 levels in HB tumors in a larger international 




3) GATA6 is overexpressed in BA and potentially drives the ductal metaplasia 
of hepatocytes 
GATA6, normally expressed in bile duct epithelium, is overexpressed in the 
hepatocytes of BA livers. This expression is significantly reduced after a successful 
alleviation of the cholestasis with PE operation. GATA6 correlates with pathological 
expansion of the bile ductules, patient age at PE, and liver injury marker ALT. In 
primary hepatocytes, GATA6 enhances the expression of genes involved in 
cholangiocyte differentiation and BA pathogenesis. Furthermore, GATA6 expression 
correlates to and colocalizes with these genes in BA livers. 
 
Future aspects: Co-culture experiments with cholangiocytes are required to explore 
the effect of intercellular signaling in GATA6 driven hepatocyte ductal metalplasia. 
Furthermore, a mouse model of BA combined with inducible hepatocyte-specific 
GATA6 knockout would shed light onto the role of GATA6 in development of DR and 
fibrosis. The final step would be unraveling the factors regulating GATA6 itself in BA 
(components of bile, cytokines and other signals of inflammation or cellular stress, 
transcription factors, growth factors etc.), thus enabling modifying these factors also 
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